

Products to help your Covid-19 Research

24, rue des Tuileries BP 684

67460 SOUFFELWEYERSHEIM CEDEX

Tél: 03 88 18 07 22 Fax: 03 88 18 07 25

e.mail: research@euromedex.com

Internet: www.euromedex.com


Table des matières

COVID-19 Scientific background	3
Virus map	3
Mechanism of the infection	3
ACE2	4
Antibodies	4
Kits for ACE2 binding inhibition testing	5
SARS-CoV-2 (COVID-19) Spike ACE2 Binding/ Neutralization Assay kit NEW!	5
CoviDrop SARS-CoV-2 Spike-ACE2 Binding Activity/Inhibition Assay Kit	6
CoviDrop SARS-CoV-2 Spike-ACE2 Binding Inhibitor Screening Fast Kit	6
CoviDrop SARS-CoV-2 Targeted Proprotein Convertase Inhibitor Screening Fast Kit	7
CoviDrop SARS-CoV-2 Targeted Proprotein Convertase Activity/Inhibition Assay Kit	8
Proteins	9
Substrate	10
Enveloppe	10
FFPE Blocks	10
Proteins	11
Furin	11
Furin Cleavage Site Blocker/Inhibitor Screening Kits	11
CoviDrop SARS-CoV-2 Specific Furin Cleavage Site (Wild Type) Blocker/Inhibitor Screening Kit	12
CoviDrop SARS-CoV-2 Specific Furin Cleavage Site (P681R Mutation) Blocker/Inhibitor Screening Kit	t 12
Membrane	13
SARS-CoV-2 Membrane Protein Proximity Ligation Assay (PLA) Kit (Cy3) NEW!	13
Antibodies	14
FFPE Blocks	14
Proteins	14
Neutralizing antibodies study	15
Kits	15
SARS-CoV-2 Neutralizing Antibody ELISA Kit (Omicron BA.1 / BA.2 / BA.4 / BA.5) NEW!	15
SeroFlash SARS-CoV-2 Neutralizing Antibody Assay Fast Kit	15
Nucleocapsid	
Antibodies	
Antibody Pairs	
FFPE Blocks	

Kits	
Overexpression Lysates	19
Proteins	20
RNA	21
2019-nCoV ValuPanel™ Reagents NEW	/ ! 21
Kits	23
SARS-CoV2-Ig	24
Kits	24
SARS-CoV2-lgG/lgM	26
Kits	26
Spike	27
Antibodies	28
Antibody Pairs	31
FFPE blocks	31
Kits	31
Overexpression Lysates	32
Proteins	32
Supplementary tools	36
3D Cell Culture	36
Antibodies	38
Inhibitors	39
Inhibitors libraries	49
Proteins	49
Substrates	50
Covidyte™ SARS-CoV-2 Substrate Series	50
Covinuto [™] ENAEO	51

COVID-19 Scientific background


Virus map



The SARS-CoV-2 virus is a positive-sense single stranded RNA virus closely related to other Severe Acute Respiratory Syndrome (SARS) coronaviruses. SARS-CoV-2 has four structural proteins, known as the S (spike), E (envelope), M (membrane), and N (nucleocapsid) proteins. The N protein holds the RNA genome, while the S, E, and M proteins together create the viral envelope. The S protein mediates viral entry into host cells by first binding to the host ACE2 receptor through the receptor-binding domain (RBD) in the S1 subunit and then fusing the viral and host membranes through the S2 subunit. The RBD residues 331 to 524 of the S1 protein elicits the production of antibodies in the host.

Source: ACS Cent. Sci. 2020,6,3,315-331

Mechanism of the infection



Source: ArigoBio

ACE2

Antibodies

Ref	Designation	Size	Host	Applications	Туре
E-AB-12224	ACE2 Polyclonal Antibody	60μL	Rabbit	IHC, ELISA	Polyclonal
E-AB-70126	ACE2 Polyclonal Antibody	120μL	Rabbit	WB	Polyclonal
EP-A73665-050	ACE2 Monoclonal Antibody	50 μΙ	Rabbit	WB, IHC	Monoclonal
EP-A73665-100	ACE2 Monoclonal Antibody	100 μΙ	Rabbit	WB, IHC	Monoclonal
EP-A73666-050	ACE2 Monoclonal Antibody	50 μΙ	Rabbit	WB, IHC	Monoclonal
EP-A73666-100	ACE2 Monoclonal Antibody	100 μΙ	Rabbit	WB, IHC	Monoclonal
GTX15349	ACE2 antibody	100 μg	Rabbit	WB, ICC/IF, IHC-P, ELISA	Polyclonal
GTX31680	ACE2 antibody	100 μg	Rabbit	WB, IHC-P, ELISA	Polyclonal
GTX135404	ACE2 antibody	100 μΙ	Rabbit	WB	Polyclonal
GTX52524	ACE2 antibody [11A31]	100 μg	Mouse	WB, IHC-P	Monoclonal
GTX101395	ACE2 antibody [N1N2], N- term	100 μΙ	Rabbit	WB, IHC-P, FACS, ELISA	Polyclonal
GTX01160	ACE2 antibody [SN0754]	100 μΙ	Rabbit	WB, ICC/IF, IHC-P	Monoclonal
GTX135403	ACE2 antibody	100 μΙ	Rabbit	WB	Polyclonal
GTX135406	ACE2 antibody	100 μΙ	Rabbit	WB	Polyclonal
GTX635897	ACE2 antibody [GT19410]	100 μΙ	Mouse	WB, IHC-P, ELISA	Monoclonal


Kits for ACE2 binding inhibition testing

SARS-CoV-2 (COVID-19) Spike ACE2 Binding/ Neutralization Assay kit

NEW

Catalog Number	Name	Size	Sample type	RUO/IVD
GTX536401	SARS-CoV-2 (COVID-19) Spike ACE2 Binding/ Neutralization Assay kit	96 Assays	 The suitable sample types include but not limit to purified antibodies and serum. The suggested sample loading amount is 50µl per well. 	RUO

Principle




A recombinant ACE2 protein is immobilized in the plate wells.

Mixtures of recombinant RBD proteins (Histagged) with Control Antibodies (both NAb and Non-NAb) or with samples are pipetted into the wells.

Neutralizing agents in the samples (or the

NAb Control Antibody solution) react with RBD proteins to prevent them from binding to ACE2. After washing away unbound proteins and antibodies, an HRP-conjugated anti-His tag antibody is added to bind to the immobilized recombinant RBD proteins. The wells are washed again to remove free conjugated antibody, and TMB substrate is added for color development. The Stop Solution changes the color from blue to yellow, and the intensity of the color (measured at 450 nm) inversely correlates with the titer of the anti-RBD neutralizing antibodies in positive samples and the NAb Control Antibody solution.

- This kit is developed for qualitative SARS-CoV-2 neutralization reagent screening.
- It includes the recombinant RBD proteins of the wildtype (WT) strain and five major WHO-designated variants of concern (i.e., Alpha, Beta, Gamma, Delta, and Kappa) for strain-specific neutralization analysis.



GTX536401 Neutralizing/Inhibition Image

Inhibition analysis of SARS-CoV-2 (COVID-19) spike neutralizing control antibody using SARS-CoV-2 (COVID-19) Spike-ACE2 Binding / Neutralization Assay Kit (GTX536401).

CoviDrop SARS-CoV-2 Spike-ACE2 Binding Activity/Inhibition Assay Kit

Catalog Number	Name	Size	Sample type	RUO/IVD
EP-D-1005-48	CoviDrop SARS-CoV-2 Spike-ACE2 Binding Activity/Inhibition Assay Kit	48 Assays	Cells, Tissues	RUO
EP-D-1005-96	CoviDrop SARS-CoV-2 Spike-ACE2 Binding Activity/Inhibition Assay Kit	96 Assays	Cells, Tissues	RUO

Principle

The CoviDrop™ SARS-CoV-2 Spike-ACE2 Binding Activity/Inhibition Assay Kit is designed for measuring SARS-CoV-2-ACE2 binding activity and inhibition using various human samples so that the functional ACE2 binding level from different cells/tissues in different individuals can be identified.

- **Fast**: Colorimetric assay with easy-to-follow steps for convenience and speed. The entire procedure can be finished within 1 hour and 45 minutes.
- **Robust**: Innovative kit composition enables background signals to be extremely low and allows the assay to be simple, accurate, reliable, and consistent.
- Convenient: Biological samples, including plasma, serum, swab samples, other body fluids, and purified proteins, can be used to detect SARS-CoV-2-ACE2 binding activity/inhibition in vivo and in vitro.
- **Sensitive and Specific**: The activity can be detected from as low as 0.1 ng of ACE2 binding and only specific for ACE2.
- Quantitative: The assay standard is included, which allows the bound ACE2 to be quantified.
- **Flexible**: Strip-well microplate format makes the assay flexible for manual or high throughput analysis

CoviDrop SARS-CoV-2 Spike-ACE2 Binding Inhibitor Screening Fast Kit

Catalog Number	Name	Size	Sample type	RUO/IVD
EP-D-1004-48	CoviDrop SARS-CoV-2 Spike-ACE2 Binding Inhibitor Screening Fast Kit	48 Assays	Antibodies, Molecule Compounds	RUO
EP-D-1004-96	CoviDrop SARS-CoV-2 Spike-ACE2 Binding Inhibitor Screening Fast Kit	96 Assays	Antibodies, Molecule Compounds	RUO

Principle

The CoviDrop™ SARS-CoV-2 Spike-ACE2 Binding Inhibitor Screening Fast Kit is designed for screening SARS-CoV-2-ACE2 binding inhibitors using purified SARS-CoV-2 spike protein and ACE2 protein in a fast and high throughput format.

- **Fast**: Colorimetric assay with easy-to-follow steps for convenience and speed. The entire procedure can be finished within 1 hour and 30 minutes.
- **Robust**: Innovative kit composition enables background signals to be extremely low and allows the assay to be simple, accurate, reliable, and consistent.

- Sensitive and Specific: The activity can be detected from as low as 0.1 ng of ACE2 binding and specific for SARS-CoV-2-ACE2 binding, which is suitable for detecting inhibitory effects of various inhibitors, specifically against SARS-CoV-2, including small molecule chemicals, therapeutic peptide or antibodies, and other biological inhibitors.
- Quantitative: The assay standard is included, which allows the bound ACE2 to be quantified.
- **Flexible**: Strip-well microplate format makes the assay flexible for manual or high throughput analysis

CoviDrop SARS-CoV-2 Targeted Proprotein Convertase Inhibitor Screening Fast Kit

Catalog Number	Name	Size	Sample type	RUO/IVD
EP-D-1006-48	CoviDrop SARS-CoV-2 Targeted Proprotein Convertase Inhibitor Screening Fast Kit	48 Assays	Molecule Compounds	RUO
EP-D-1006-96	CoviDrop SARS-CoV-2 Targeted Proprotein Convertase Inhibitor Screening Fast Kit	96 Assays	Molecule Compounds	RUO

Principle

The CoviDrop™ SARS-CoV-2 Targeted Proprotein Convertase Inhibitor Screening Fast Kit is a complete set of optimized buffers and reagents designed for screening inhibitors of SARS-CoV-2-specific proprotein convertase (PC) such as furin and other serine proteases that may also target the PC cleavage motif in SARS-CoV-2 in a fast and high throughput format.

- **Fast**: Colorimetric assay with easy-to-follow steps for convenience and speed. The entire procedure can be finished within 2 hours.
- Robust: Innovative kit composition enables background signals to be extremely low and allows the
 assay to be simple, accurate, reliable, and consistent.
- **Sensitive**: The activity can be detected from as low as 2 ng of PC (ex: furin) or facilitated serine protease (ex: HAT).
- **Specific**: The substrate contains the entire SARS-CoV-2 S1/S2 cleavage sequence and is proven to be the same as real spike protein with tertiary structure in PC cleavage tests. Thus, the assay is uniquely specific for detecting SARS-CoV-2 S1/S2 cleavage and is suitable for measuring inhibitory effects of various inhibitors against SARS-CoV-2-targeted cleavage PCs, including small molecule chemicals, therapeutic peptide, or other biological inhibitors.
- **Flexible**: Strip-well microplate format makes the assay flexible for manual or high throughput analysis

CoviDrop SARS-CoV-2 Targeted Proprotein Convertase Activity/Inhibition Assay Kit

Catalog Number	Name	Size	Sample type	RUO/IVD
EP-D-1007-48	CoviDrop SARS-CoV-2 Targeted Proprotein Convertase Activity/Inhibition Assay Kit	48 Assays	Cells, Tissues	RUO
EP-D-1007-96	CoviDrop SARS-CoV-2 Targeted Proprotein Convertase Activity/Inhibition Assay Kit	96 Assays	Cells, Tissues	RUO

Principle

The CoviDrop™ SARS-CoV-2 Targeted Proprotein Convertase Activity/Inhibition Assay Kit is a complete set of optimized buffers and reagents designed for measuring SARS-CoV-2-targeted proprotein convertase (PC) cleavage activity and inhibition using various human samples so that the functional PC activity targeting SARS-CoV-2 S1/S2 site cleavage can be identified.

- **Fast**: Colorimetric assay with easy-to-follow steps for convenience and speed. The entire procedure can be finished within 50 min.
- **Robust**: Innovative kit composition enables background signals to be extremely low and allows the assay to be simple, accurate, reliable, and consistent.
- **Sensitive**: The activity can be detected from as low as 2 ng of PC (ex: furin) or facilitated serine protease.
- **Specific**: The substrate contains entire SARS-CoV-2-S1/S2 cleavage sequence and is proven to be the same as complete trimeric form of full-length SARS-CoV-2 spike protein in proprotein convertase (PC) cleavage tests. Thus, the assay is uniquely specific for detecting SARS-CoV-2-S1/S2 cleavage and is suitable for measuring inhibitory effects of various intervention against SARS-CoV-2-targeted PCs.
- **Flexible**: Strip-well microplate format makes the assay flexible for manual or high throughput analysis.

Proteins

Ref	Designation	Size	Expression system	Tag
AL-RP01275	Recombinant Human ACE2 Protein with hFc tag	100 μg	HEK293T	C-hFc
AL-RP01266	Recombinant Human ACE2 Protein with His and Avi t	100 μg	HEK293T	C-Avi-6His
AL-RP01276	Recombinant Human ACE2 Protein with His tag	100 μg	HEK293T	C-6His
E-PKSR030493	Recombinant Human ACE2 Protein (Avi-His Tag)	20 μg	Human Cells	C-Avi-6His
E-PKSR030492	Recombinant Human ACE2 Protein (Fc Tag)	10 μg	Human Cells	C-Fc
E-PKSH030457	Recombinant Human ACE2 Protein (Fc Tag)(Active)	20 μg	Human Cells	C-Fc
E-PKSH032068	Recombinant Human ACE2 Protein (His Tag)	10 μg	Human Cells	C-6His
E-PKSR030494	Recombinant Human ACE2 Protein (mFc Tag)	10 μg	Human Cells	C-mFc
EP-E80019-1	ACE2, His-Tag Protein	20 μg	HEK293 cells	His-Tag
EP-E80019-2	ACE2, His-Tag Protein	100 μg	HEK293 cells	His-Tag
EP-E80013-1	Recombinant ACE2 Protein with hFc Tag	100 μg	HEK293 cells	hFc Tag
EP-E80008-1	Recombinant ACE2 Protein with His and Avi Tag	100 μg	HEK293 cells	His and Avi Tag
EP-E80014-1	Recombinant ACE2 Protein with His-Tag	100 μg	HEK293 cells	His-Tag
GTX15354	ACE2 peptide (169-183)	50 μg		
GTX15351	ACE2 peptide (192-208)	50 μg		
GTX15353	ACE2 peptide (2-18)	50 μg		
GTX15352	ACE2 peptide (788-805)	50 μg		
GTX135683-pro	Human ACE2 (ECD) protein , mouse IgG Fc tag	100 μg	HEK293	Fc-Tag
GTX01550-pro	Human ACE2 protein, His and Avi tag	100 μg	HEK293	His-Avi Tag

Substrate

ACE2 (angiotensin-converting enzyme 2) is a metalloproteinase that requires a divalent cation positioned at the active site in order to perform catalysis. It has multiple physiological roles that revolve around its trivalent function: a negative regulator of the renin-angiotensin system, facilitator of amino acid transport, and the severe acute respiratory syndrome-coronavirus (SARS-CoV) and SARS-CoV-2 receptor. ACE2 has recently been identified as the SARS-CoV-2 receptor, the infective agent responsible for the coronavirus disease, providing a critical link between immunity, inflammation, ACE2, and cardiovascular disease. Although sharing a close evolutionary relationship with SARS-CoV, the receptor-binding domain of SARS-CoV-2 differs in several key amino acid residues, allowing for stronger binding affinity with the human ACE2 receptor, which may account for the greater pathogenicity of SARS-CoV-2. The loss of ACE2 function following binding by SARS-CoV-2 is driven by endocytosis and activation of proteolytic cleavage and processing. The ACE2 system is a critical protective pathway against heart failure with reduced and preserved ejection fraction including, myocardial infarction and hypertension, and against lung disease and diabetes mellitus. The control of gut dysbiosis and vascular permeability by ACE2 has emerged as an essential mechanism of pulmonary hypertension and diabetic cardiovascular complications. Mca-APK(Dnp) ACE2 substrate is a FRET peptide for measuring enzymatic activity in cells and tissues. It uses DNP as a quencher molecule to quench the fluorescence of methoxycoumarin (Mca). This interaction is abolished when the enzyme cleaves the proline-lysine residue and restore the fluorescence of Mca. This fluorogenic substrate offers more flexibility and higher throughput than the commonly used HPLC-separation-based methods.

Catalog Number	Name	Size	Molecular weight	Emission (nm)	Excitation (nm)
13555-AAT	Mca-APK(Dnp) ACE2 substrate	1 mg	696,67	322	381
13556-AAT	Mca-APK(Dnp) ACE2 substrate	10 mg	696,67	322	381

Enveloppe

FFPE Blocks

Ref	Designation	Application
GTX435642	SARS-CoV-2 (COVID-19) Envelope FFPE Cell Pellet Block	IHC-P

Proteins

Ref	Designation	Size	Expression system	Tag
AL-RP01263LQ	Recombinant 2019-nCoV envelope Protein with His tag and Avi tag	100 μg	E.coli	N-Avi-6His
E-PKSR030488	Recombinant 2019-nCoV Envelope Protein (His Tag)	1 mg	E.coli	N-6His
EP-E80005-1	Recombinant SARS-CoV-2 envelope Protein with His and Avi Tag	100 μg	E. coli	His and Avi Tag
GTX01565-pro	SARS-CoV-2 (COVID-19) Envelope Protein, GST and His Tag	100 μg	HEK293	GST and His Tag
GTX01547-pro	SARS-CoV-2 (COVID-19) Envelope protein, His and Avi tag	100 μg	E. coli	His-Avi Tag
PR-AG30690	2019-nCOV envelope protein Fusion Protein	50 μg	E. coli	GST

Furin

Furin Cleavage Site Blocker/Inhibitor Screening Kits

COVID-19 is an infectious disease caused by SARS-CoV-2, a new member of the same coronavirus family that caused SARS and MERS. It was found that the SARS-CoV-2 spike glycoprotein harbors a furin cleavage site (FCS) at the boundary between the S1/S2 subunits, which could be cleaved by furin and/or furin-like Protein Convertases (PC) secreted from host cells and bacteria in the airway epithelium. Unlike SARS-CoV, cell entry of SARS-CoV-2 is pre-activated by furin and/or furin-like PCs, reducing its dependence on target cell proteases for entry. The cleavage activation of S-protein is well demonstrated to be essential for SARS-CoV-2 spike-mediated viral binding to ACE2, cell-cell fusion, and viral entry into human lung cells. The SARS-CoV-2 furin/PC cleavage site has one core region SPRRAR | SV (eight amino acids, P6-P2). The core region is very unique as its P2 and P3 positions are positively charged residues (Arg), and another residue is hydrophobic (Ala). This status allows such sites to be cleaved by furin or furin-like PC and the cleavage efficiency facilitated by other serine proteases targeting dibasic amino acid sites such as human airway trypsin (HAT). It is well known that SARS-CoV-2 S1/S2 cleavage increases SARS-CoV-2 entry into cells and replication, eventually leading to higher transmission and pathogenicity of COVID-19. Thus, inhibition of SARS-CoV-2 S1/S2 cleavage would allow for the reduction of FCS cleavage-based activation of SARS-CoV-2 spike protein, thereby decreasing viral binding to ACE2, cell-cell fusion, and viral entry into human cells. There are two approaches to block or reduce S1/S2 cleavage of the spike proteins. One approach is based on the inhibition of furin or furin-like protease activity against FCS. For example, peptide or small molecular inhibitors could be used to inhibit furin or furin-like protease activity. Another one is to block SARS-CoV-2 FCS directly. For example, antibody or peptide ligands could be used as blockers against SARS-CoV-2 FCS, avoiding or reducing the disadvantages of inhibiting host furin and furin-like proteases; as such inhibition could non-specifically cause damage to the normal functions of the proteins that need activation by these enzymes. Screening blockers and/or inhibitors of SARS-CoV-2 FCS would help to develop effective drugs for COVID-19 therapy by blocking SARS-CoV-2 cleavage at S1/S2 boundary site.

CoviDrop SARS-CoV-2 Specific Furin Cleavage Site (Wild Type) Blocker/Inhibitor Screening Kit

Ref	Size	Designation	Application
EP-D-1009-096	96 Assays	CoviDrop SARS-CoV-2 Specific Furin Cleavage Site (Wild Type)	RUO
EP-D-1009-192	192 Assays	Blocker/Inhibitor Screening Kit	RUO

The CoviDrop™ SARS-CoV-2 Specific Furin Cleavage Site (Wild Type) Blocker/Inhibitor Screening Kit is a complete set of optimized buffers and reagents designed for screening Blockers of SARS-CoV-2 specific furin cleavage site (FCS) and/or inhibitors of furin and other serine proteases such as human air trypsin (HAT) that may also target the FCS of SARS-CoV-2 in a fast and high throughput format. The kit has the following advantages:

- **Fast**: Colorimetric assay with easy-to-follow steps for convenience and speed. The entire procedure can be finished within 1 hour and 10 min.
- **Robust**: Innovative kit composition enables background signals to be extremely low and allows the assay to be simple, accurate, reliable, and consistent.
- **Dual-Function**: The kit allows for screening of both SARS-CoV-2 FCS direct blockers or furin and furin-like protease activity inhibitors.
- Specific: The substrate contains the entire SARS-CoV-2-S1/S2 cleavage sequence and is proven to be the same as the complete trimeric form of full-length SARS-CoV-2 spike protein in PC cleavage tests. Thus, the assay is uniquely specific for detecting SARS-CoV-2-S1/S2 cleavage and its inhibition by various blockers/inhibitors including small molecule chemicals, therapeutic peptides, antibodies, or other biological inhibitors.


CoviDrop SARS-CoV-2 Specific Furin Cleavage Site (P681R Mutation) Blocker/Inhibitor Screening Kit

Ref	Size	Designation	Application
EP-D-1010-096	96 Assays	CoviDrop SARS-CoV-2 Specific Furin Cleavage Site (P681R	RUO
EP-D-1010-192	192 Assays	Mutation) Blocker/Inhibitor Screening Kit	RUO

The CoviDrop™ SARS-CoV-2 Specific Furin Cleavage Site (P681R Mutation) Blocker/Inhibitor Screening Kit is a complete set of optimized buffers and reagents designed for screening Blockers of SARS-CoV-2 specific furin cleavage site (FCS) and/or inhibitors of furin and other serine proteases such as human air trypsin (HAT) that may also target the FCS of SARS-CoV-2 in a fast and high throughput format. The kit has the following advantages:

- **Fast**: Colorimetric assay with easy-to-follow steps for convenience and speed. The entire procedure can be finished within 1 hour and 10 min.
- **Robust**: Innovative kit composition enables background signals to be extremely low and allows the assay to be simple, accurate, reliable, and consistent.
- **Dual-Function**: The kit allows for screening of both SARS-CoV-2 P681R mutated FCS direct blockers or furin and furin-like protease activity inhibitors.
- **Specific**: The substrate contains the entire SARS-CoV-2-S1/S2 cleavage sequence with P681R mutation. Thus, the assay is uniquely specific for detecting SARS-CoV-2 P681R mutated FCS cleavage and its inhibition by various blockers/inhibitors including small molecule chemicals, therapeutic peptides, antibodies, or other biological inhibitors.


• **Flexible**: Stripwell microplate format makes the assay flexible for manual or high throughput analysis.



Schematic procedure of the CoviDrop™ SARS-CoV-2 Specific Furin Cleavage Site Blocker/Inhibitor Screening Kit.

Membrane

SARS-CoV-2 Membrane Protein Proximity Ligation Assay (PLA) Kit (Cy3) NEW!



GTX537371-23 PLA Image

Detection of SARS-CoV-2 (COVID-19) membrane protein in a transfected HEK293T cell FFPE Cell Pellet Block (GTX435645) section using the SARS-CoV-2 Membrane Protein Proximity Ligation Assay Kit (Cy3) (GTX537371-23). PLA signals appear yellow and nuclei are blue.

- A) Positive PLA reaction in transfected HEK293T cells.
- B) Negative control with mock-transfected HEK293T cells.
- C) Negative control using one non-specific PLA antibody probe in transfected HEK293T cells.

The SARS-CoV-2 Membrane Protein Proximity Ligation Assay (PLA) Kit (Cy3) enables the detection of SARS-CoV-2 membrane protein in virus-infected tissue or infected/transfected cell block samples. The viral membrane protein is detected using two oligonucleotide-conjugated primary antibodies, called PLA probes. Only when both PLA probes bind to the membrane protein can the assay generate an amplified signal. This provides researchers with a highly specific and sensitive diagnostic tool.

Components

Item	Name	Quantity	Storage
A1	Blocking Solution, 10 mL	2 bottles QSP 5 tests	- 20 ºC
A2	Antibody (Ab)-Oligo A, 40 μL	1 tube QSP 5 tests	- 20 ºC
A3	Antibody (Ab)-Oligo B, 40 μL	1 tube QSP 5 tests	- 20 ºC
A4	Ligase (400 U/μL), 10 μL	1 tube QSP 5 tests	- 20 ºC
A5	5x Ligation Solution, 500 μL	1 tube QSP 5 tests	- 20 ºC
A6	Polymerase (10 U/μL), 10 μL -	1 tube QSP 5 tests	- 20 ºC
A7	5x Amplification Solution, 500 μL	1 tube QSP 5 tests	- 20 ºC
A8	Detection Probe (Cy3), 50 μL	1 tube- QSP 5 tests	- 20 ºC
B1	10x Probe Solution, 200 μL	1 tube QSP 5 tests	4°C or below
B2	20x Wash Buffer, 50 mL	2 bottles QSP 5 tests	4°C or below

Antibodies

Ref	Designation	Size	Host	Applications	Mono/poly
GTX134866	MERS-CoV M protein antibody	100 μΙ	Rabbit	WB	Polyclonal
GTX134866-S	MERS-CoV M protein antibody	25 μΙ	Rabbit	WB	Polyclonal
GTX83199	SARS-CoV M antibody [2H2C4]	100 μΙ	Mouse	WB, ELISA	Monoclonal
GTX64544	TMPRSS2 antibody	100 μΙ	Rabbit	WB, IHC-P	Polyclonal
GTX100743-S	TMPRSS2 antibody [N2C3]	25 μΙ	Rabbit	WB, IHC-P	Polyclonal
GTX100743	TMPRSS2 antibody [N2C3]	100 μΙ	Rabbit	WB, IHC-P	Polyclonal
GTX81494	TMPRSS2 antibody, Internal	400 μΙ	Rabbit	WB, FACS	Polyclonal
EP-A73667-050	TMPRSS2 Monoclonal Antibody	50 μΙ	Rabbit	WB, IHC	Monoclonal
EP-A73667-100	TMPRSS2 Monoclonal Antibody	100 μΙ	Rabbit	WB, IHC	Monoclonal
EP-A73681-050	TMPRSS2 Recombinant Antibody	50 μΙ	Rabbit	ELISA, WB	Recombinant
EP-A73681-100	TMPRSS2 Recombinant Antibody	100 μΙ	Rabbit	ELISA, WB	Recombinant

FFPE Blocks

Ref	Designation	Application
GTX435645	SARS-CoV-2 (COVID-19) Membrane FFPE Cell Pellet Block	IHC-P

Proteins

Ref	Designation	Size	Expression system	Tag
PR-AG30692	Membrane glycoprotein Fusion Protein	50 μg	E. coli	His-Tag
EP-E80017-2	Recombinant TMPRSS2 Protein, Partial	100 μg	E.coli	
EP-E80017-3	Recombinant TMPRSS2 Protein, Partial	1 mg	E.coli	
EP-E80017-1	Recombinant TMPRSS2 Protein, Partial	20 μg	E.coli	
EP-E80016-1	Recombinant Transmembrane Protease Serine 2 Protein, Partial	20 μg	Yeast	
EP-E80016-2	Recombinant Transmembrane Protease Serine 2 Protein, Partial	100 μg	Yeast	
EP-E80016-3	Recombinant Transmembrane Protease Serine 2 Protein, Partial	500 μg	Yeast	

Neutralizing antibodies study


Kits

SARS-CoV-2 Neutralizing Antibody ELISA Kit (Omicron BA.1 / BA.2 / BA.4 / BA.5) NEW!

New SARS-CoV-2 Omicron subvariants are rapidly spreading worldwide due to their enhanced immune evasion properties. Detection of anti-spike neutralizing antibodies (NAbs) can be used as a measurable indicator of protective immunity to these subvariants. NAbs inhibit binding of the SARS-CoV-2 spike protein receptor-binding domain (RBD) to the host cell ACE2 receptor. Studies indicate the crucial roles of NAbs for patient survival and viral control. A better understanding of the strength and duration of immune protection is important for epidemiological studies, public health measures, and future vaccination campaigns.

NAb levels are generally measured using live virus-based inhibition assays. However, these require several days to perform and become cumbersome when processing a large number of samples. High-throughput immunoassays are able to report the presence of anti-RBD or anti-spike antibodies and establish a correlation with neutralizing activity.

GeneTex has streamlined the immunoassay-based neutralizing antibody detection process by creating the SARS-CoV-2 Neutralizing Antibody ELISA Kit (Omicron BA.1 / BA.2 / BA.4 / BA.5) (GTX537233) (see schematic below).



The kit employs a competitive ELISA strategy with plate-immobilized recombinant ACE2 protein bound by soluble recombinant His-tagged trimeric spike ECD proteins from wildtype SARS-CoV-2, Omicron BA.1, Omicron BA.2, or Omicron BA.4/5. Test and control samples are first applied to the wells to allow binding of any NAb in the sample to the subsequently added spike proteins. Both neutralizing (positive control; NAb) and non-neutralizing (negative control; Non-NAb) antibodies for semi-quantification of the neutralization capability of each test sample are included. Assay readout is generated by an HRP-conjugated anti-His tag antibody that binds to the bound spike protein with TMB signal development. The kit is compatible with the Dynex DS2® automatic ELISA system and is thus ideal for high-throughput analysis.

Catalog Number	Name	Size	Sample type	RUO /IVD
GTX537233	SARS-CoV-2 Neutralizing Antibody ELISA Kit (Omicron BA.1 / BA.2 / BA.4 / BA.5)	96 Assays	Serum, Plasma, Various Body Fluids	RUO

SeroFlash SARS-CoV-2 Neutralizing Antibody Assay Fast Kit

Catalog Number	Name	Size	Sample type	RUO /IVD
EP-D-1008-48	SeroFlash SARS-CoV-2 Neutralizing Antibody Assay Fast Kit	48 Assays	Serum, Plasma, Various Body Fluids	RUO
EP-D-1008-96	SeroFlash SARS-CoV-2 Neutralizing Antibody Assay Fast Kit	96 Assays	Serum, Plasma, Various Body Fluids	RUO

The SeroFlash™ SARS-CoV-2 Neutralizing Antibody Assay Fast Kit is a complete set of optimized buffers and reagents designed for detecting and quantifying SARS-CoV-2 neutralizing antibody in circulation in a fast and high throughput format

- **Fast**: Colorimetric assay with easy-to-follow steps for convenience and speed. The entire procedure can be finished within 50 minutes
- **Robust**: Innovative kit composition enables background signals to be extremely low and allows the assay to be simple, accurate, reliable, and consistent.
- Sensitive and Specific: The neutralizing antibody level can be detected from as low as 1 ng and is specific for SARS-CoV-2, which is suitable for identifying whether neutralizing antibody is present in infected individuals and distinguishing SARS-CoV-2 neutralizing antibody from other antibodies.
- Quantitative: The assay standard is included, which allows the neutralizing antibody titer or concentration to be quantified for EC50 calculation.
- **Flexible**: Strip-well microplate format makes the assay flexible for manual or high throughput analysis

Nucleocapsid

Coronaviruses are enveloped viruses with a positive-sense RNA genome and with a nucleocapsid of helical symmetry. Coronavirus nucleoproteins localize to the cytoplasm and the nucleolus, a subnuclear structure, in both virus-infected primary cells and in cells transfected with plasmids that express N protein. Coronavirus N protein is required for coronavirus RNA synthesis, and has RNA chaperone activity that may be involved in template switch. Nucleocapsid protein is a most abundant protein of coronavirus. During virion assembly, N protein binds to viral RNA and leads to formation of the helical nucleocapsid. Nucleocapsid protein is a highly immunogenic phosphoprotein also implicated in viral genome replication and in modulating cell signaling pathways. Because of the conservation of N protein sequence and its strong immunogenicity, the N protein of coronavirus is chosen as a diagnostic tool.

Antibodies

Ref	Designation	Size	Host	Applications	Mono/poly
21802-1-SAB	2019-nCoV NP Antibody	50 μg	Human	Diagnostic	Monoclonal
21802-2-SAB	2019-nCoV NP Antibody	1 mg	Human	Diagnostic	Monoclonal
80026-1-RR	2019-nCOV nucleocapsid phosphoprotein Recombinant antibody [489]	100 μΙ	Rabbit	WB, ELISA	Monoclonal
80027-1-RR	2019-nCOV nucleocapsid phosphoprotein Recombinant antibody [8C20]	100 μΙ	Rabbit	WB, ELISA	Monoclonal
GTX134868	MERS-CoV Nucleoprotein antibody	100 μΙ	Rabbit	WB	Polyclonal
GTX134868-S	MERS-CoV Nucleoprotein antibody	25 μΙ	Rabbit	WB	Polyclonal
ARG66735	SARS-CoV / SARS-CoV-2 nucleocapsid protein antibody [SQab20177]	100 μg	Human	ELISA, ICC/IF, WB	Monoclonal
GTX632269	SARS-CoV Nucleocapsid antibody [6H3]	100 μΙ	Mouse	WB, ICC/IF, IHC-P	Monoclonal

Ref	Designation	Size	Host	Applications	Mono/poly
GTX632269-S	SARS-CoV Nucleocapsid antibody [6H3]	25 μΙ	Mouse	WB, ICC/IF,	Monoclonal
	, , , , , , , , , , , , , , , , , , ,			IHC-P	
GTX36802	SARS-CoV Nucleoprotein antibody [3851]	500 μl	Mouse	WB, ICC/IF,	Monoclonal
		·		ELISA	
GTX36801	SARS-CoV Nucleoprotein antibody [3861]	500 μl	Mouse	WB, ICC/IF,	Monoclonal
				ELISA	
E-AB-V1011	SARS-COV/SARS-COV-2 NP Monoclonal	100 μΙ	Mouse /	ELISA	Monoclonal
	Antibody(2019-nCoV)		Human		
E-AB-V1013	SARS-COV/SARS-COV-2 NP Monoclonal	100 μΙ	Mouse	WB,ELISA	Monoclonal
	Antibody(2019-nCoV)				
E-AB-V1014	SARS-COV/SARS-COV-2 NP Monoclonal	100 μl	Rabbit	WB,ELISA	Monoclonal
	Antibody(2019-nCoV)				
21805-1-SAB	SARS-CoV-2 (2019-nCoV) Nucleoprotein /	50 μl	Rabbit	WB	Monoclonal
	NP Antibody				
21805-2-SAB	SARS-CoV-2 (2019-nCoV) Nucleoprotein /	100 μl	Rabbit	WB	Monoclonal
	NP Antibody			_	
GTX135357	SARS-CoV-2 (COVID-19) nucleocapsid	100 μl	Rabbit	WB, ICC/IF,	Polyclonal
	antibody			IHC-P	
GTX135357-S	SARS-CoV-2 (COVID-19) nucleocapsid	25 μl	Rabbit	WB, ICC/IF,	Polyclonal
071/407064	antibody	100 1	5 111	IHC-P	
GTX135361	SARS-CoV-2 (COVID-19) nucleocapsid	100 μΙ	Rabbit	WB	Polyclonal
CTV425264 6	antibody	25	D. L.L.)4/B	Dal dand
GTX135361-S	SARS-CoV-2 (COVID-19) nucleocapsid	25 μΙ	Rabbit	WB	Polyclonal
CTVC2F000	antibody	100	Mausa	\A/D	Monoclonal
GTX635808	SARS-CoV-2 (COVID-19) nucleocapsid antibody [GT113]	100 μΙ	Mouse	WB	IVIONOCIONAI
GTX635808-S	SARS-CoV-2 (COVID-19) nucleocapsid	25 μΙ	Mouse	WB	Monoclonal
G1X033808-3	antibody [GT113]	25 μι	Wiouse	VVD	Wioriocional
GTX635680	SARS-CoV-2 (COVID-19) nucleocapsid	100 μΙ	Rabbit	WB	Monoclonal
G17655666	antibody [HL146]	100 μι	Rabbie	***	Wichiocional
GTX635680-S	SARS-CoV-2 (COVID-19) nucleocapsid	25 μΙ	Rabbit	WB	Monoclonal
	antibody [HL146]				
GTX635678	SARS-CoV-2 (COVID-19) nucleocapsid	100 μl	Rabbit	WB, ELISA	Monoclonal
	antibody [HL249]	·		ŕ	
GTX635678-S	SARS-CoV-2 (COVID-19) nucleocapsid	25 μΙ	Rabbit	WB, ELISA	Monoclonal
	antibody [HL249]				
GTX635679	SARS-CoV-2 (COVID-19) nucleocapsid	100 μΙ	Rabbit	WB, ELISA	Monoclonal
	antibody [HL344]				
GTX635679-S	SARS-CoV-2 (COVID-19) nucleocapsid	25 μΙ	Rabbit	WB, ELISA	Monoclonal
	antibody [HL344]				
GTX635686-S	SARS-CoV-2 (COVID-19) nucleocapsid	25 μΙ	Rabbit	WB, ICC/IF,	Monoclonal
	antibody [HL448]			ELISA	
GTX635686*	SARS-CoV-2 (COVID-19) nucleocapsid	100 μl	Rabbit	WB, ICC/IF,	Monoclonal
	antibody [HL448]			ELISA/LFA	
GTX635686-01	SARS-CoV-2 (COVID-19) nucleocapsid	50 μl	Rabbit	ELISA	Monoclonal
CTVC25C25	antibody [HL448] (HRP)	25 '	D. I. I. II	14/0-100/15	
GTX635687-S	SARS-CoV-2 (COVID-19) nucleocapsid	25 μΙ	Rabbit	WB, ICC/IF,	Monoclonal
CTVC25C07	antibody [HL453]	100	Dale le la	ELISA	NA - w I - I
GTX635687	SARS-CoV-2 (COVID-19) nucleocapsid	100 μΙ	Rabbit	WB, ICC/IF,	Monoclonal
	antibody [HL453]			ELISA	

Ref	Designation	Size	Host	Applications	Mono/poly
GTX635688-S	SARS-CoV-2 (COVID-19) nucleocapsid antibody [HL455]	25 μΙ	Rabbit	WB, ICC/IF, ELISA, sELISA	Monoclonal
GTX635688**	SARS-CoV-2 (COVID-19) nucleocapsid antibody [HL455]	100 μΙ	Rabbit	WB, ICC/IF, ELISA, sELISA/LFA	Monoclonal
GTX635712-S	SARS-CoV-2 (COVID-19) nucleocapsid antibody [HL455-MS]	25 μΙ	Mouse	WB, ICC/IF, ELISA, sELISA	Monoclonal
GTX635712	SARS-CoV-2 (COVID-19) nucleocapsid antibody [HL455-MS]	100 μΙ	Mouse	WB, ICC/IF, ELISA, sELISA	Monoclonal
GTX635685-S	SARS-CoV-2 (COVID-19) nucleocapsid antibody [HL5410]	25 μΙ	Rabbit	WB, ELISA, sELISA	Monoclonal
GTX635685**	SARS-CoV-2 (COVID-19) nucleocapsid antibody [HL5410]	100 μΙ	Rabbit	WB, ELISA, sELISA/LFA	Monoclonal
GTX635689-S	SARS-CoV-2 (COVID-19) nucleocapsid antibody [HL5511]	25 μΙ	Rabbit	WB, ICC/IF, ELISA	Monoclonal
GTX635689*	SARS-CoV-2 (COVID-19) nucleocapsid antibody [HL5511]	100 μΙ	Rabbit	WB, ICC/IF, ELISA/LFA	Monoclonal
EP-A73663-050	SARS-CoV-2 N Protein Monoclonal Antibody	50 μΙ	Rabbit	WB, ELISA, FCM, IHC, IF, IP	Monoclonal
EP-A73663-100	SARS-CoV-2 N Protein Monoclonal Antibody	100 μΙ	Rabbit	WB, ELISA, FCM, IHC, IF, IP	Monoclonal
EP-A73671-100	SARS-CoV-2 N Recombinant Antibody	100 μΙ	Mouse	ELISA, GICA	Recombinant
EP-A73676-100	SARS-CoV-2 N Recombinant Antibody	100 μΙ	Mouse	ELISA, WB, GICA	Recombinant
EP-A73679-050	SARS-CoV-2 N Recombinant Antibody, Biotin Conjugated	50 μΙ	Mouse	ELISA	Recombinant
EP-A73679-100	SARS-CoV-2 N Recombinant Antibody, Biotin Conjugated	100 μΙ	Mouse	ELISA	Recombinant
EP-A73678-050	SARS-CoV-2 N Recombinant Antibody, FITC Conjugated	50 μΙ	Mouse	ELISA	Recombinant
EP-A73678-100	SARS-CoV-2 N Recombinant Antibody, FITC Conjugated	100 μΙ	Mouse	ELISA	Recombinant
EP-A73677-050	SARS-CoV-2 N Recombinant Antibody, HRP Conjugated	50 μΙ	Mouse	ELISA	Recombinant
EP-A73677-100	SARS-CoV-2 N Recombinant Antibody, HRP Conjugated	100 μΙ	Mouse	ELISA	Recombinant

^{*} and ** design recommended antibody pairs for lateral flow assay (LFA)

Antibody Pairs

Ref	Designation	Size	Host	Applications	Mono/poly
GTX500042	SARS-CoV-2 (COVID-19) Nucleocapsid ELISA Pair [HL5410 / HL455-MS]	1 pair		ELISA	
GTX500045	SARS-CoV-2 (COVID-19) nucleocapsid ELISA Pair [HL5511 / HL448]	1 pair		ELISA	

FFPE Blocks

Ref	Designation	Application
GTX435641	SARS-CoV-2 (COVID-19) Nucleocapsid FFPE Cell Pellet Block	IHC-P

Kits

Catalog Number	Name	Size	Principle	Sample type	RUO /IVD
AL-RK04136	2019-nCoV Nucleocapsid Protein Elisa Kit	96T	The ELISA (Enzyme-Linked Immunosorbent Assay) kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of samples in serum, plasma (EDTA, citrate, heparin).	Serum, plasma	RUO
E-EL-E600	SARS-CoV-2 Nucleocapsid Protein IgG ELISA Kit	96T	This ELISA kit uses Indirect-ELISA as the method to qualitatively detect the SARS-CoV-2 Nucleocapsid protein IgG in the sample.	serum, plasma	RUO
E-EL-E601	SARS-CoV-2 Nucleocapsid Protein IgM ELISA Kit	96T	This ELISA kit uses Indirect-ELISA as the method to qualitatively detect the SARS-CoV-2 Nucleocapsid protein IgM in the sample.	serum, plasma	RUO
GTX535824	SARS-CoV-2 (COVID-19) Nucleocapsid Protein Sandwich ELISA Kit	96T	The GeneTex SARS-CoV-2 (COVID-19) Nucleocapsid Protein Sandwich ELISA kit is an in vitro assay tool for the quantitative measurement of SARS-CoV-2 nucleocapsid protein. This assay employs a pair of monoclonal antibodies specific for SARS-CoV-2 nucleocapsid protein, with the lowest detectable dose concentration of standard protein being 18 pg/ml.	cell culture supernatant , plasma and serum	RUO

Overexpression Lysates

Ref	Designation	Application
GTX535665	SARS-CoV-2 (COVID-19) Nucleocapsid overexpression 293T whole cell lysate	WB, ELISA

Proteins

Ref	Designation	Size	Expression	Tag
			system	
ARG70223	HCoV-229E nucleocapsid recombinant protein	100 μg	E. coli	His-Tag
ARG70222	HCoV-HKU1 nucleocapsid recombinant protein	100 μg	E. coli	His-Tag
ARG70221	HCoV-OC43 nucleocapsid recombinant protein	100 μg	E. coli	His-Tag
GTX135653-pro	MERS-CoV nucleocapsid protein	100 μg	HEK293	
PR-AG30676	Nucleocapsid phosphoprotein Fusion Protein	50 μg	E. coli	His-Tag
AP89517-SAB	Recombinant 2019-nCoV Nucleocapsid Protein	1 mg	E. coli	His-Tag
PKSR030485	Recombinant 2019-nCoV Nucleocapsid Protein (His Tag)	1 mg	E.coli	N-6His
PKSR030497	Recombinant 2019-nCoV Nucleocapsid Protein (His Tag)	100 μg	Baculovirus- Insect Cells	C-6His
AL-RP01264LQ	Recombinant 2019-nCoV Nucleocapsid Protein with His tag	100 μg	E.coli	N-6His
AP89513-1-SAB	Recombinant Human Novel Coronavirus Nucleoprotein(N)	100 μg	E. coli	His-Tag
CC-RPX274Ge01- 10UG	Recombinant Nucleoprotein (NP)	10 μg	E. coli	His-Tag
CC-RPX274Ge01- 50UG	Recombinant Nucleoprotein (NP)	50 μg	E. coli	His-Tag
CC-RPX274Ge01- 200UG	Recombinant Nucleoprotein (NP)	200 μg	E. coli	His-Tag
CC-RPX274Ge01- 1MG	Recombinant Nucleoprotein (NP)	1mg	E. coli	His-Tag
EP-E80006-1	Recombinant SARS-CoV-2 Nucleocapsid Protein with His-Tag	100 μg	E. coli	His-Tag
GTX135357-pro	SARS-CoV-2 (COVID-19) nucleocapsid protein	500 μg	E. coli	His-Tag
GTX135357-pro-S	SARS-CoV-2 (COVID-19) nucleocapsid protein	100 μg	E. coli	His-Tag
GTX135592-pro	SARS-CoV-2 (COVID-19) nucleocapsid protein	100 μg	HEK293	His-Tag
GTX137882-pro	SARS-CoV-2 (COVID-19) Nucleocapsid protein, Omicron / BF.7 variant, His tag	100 μg	HEK293	His-Tag NEW!
GTX137883-pro	SARS-CoV-2 (COVID-19) Nucleocapsid protein, Omicron / BQ.1 variant, His tag	100 μg	HEK293	His-Tag NEW!
EP-E80027-1	SARS-CoV-2 Nucleocapsid Protein, Avi-His-tag	100 μg	HEK293 cells	Avi and His Tag
EP-E80027-2	SARS-CoV-2 Nucleocapsid Protein, Avi-His-tag	1 mg	HEK293 cells	Avi and His Tag
EP-E80028-1	SARS-CoV-2 Nucleocapsid Protein, Avi-His-tag	20 μg	Mammalian cell	Avi and His Tag
EP-E80028-2	SARS-CoV-2 Nucleocapsid Protein, Avi-His-tag	100 μg	Mammalian cell	Avi and His Tag
ARG70217	SARS-CoV-2 nucleocapsid recombinant protein	100 μg	E. coli	
ARG70216	SARS-CoV-2 nucleocapsid recombinant protein	100 μg	HEK293	His-SUMO Tag

RNA

2019-nCoV ValuPanel™ Reagents

2019-nCoV ValuPanel™ Reagents are separately delivered probes and primers for RT-PCR detection of the genetic sequence of SARS-CoV-2.

For Research Use Only. Not for use in diagnostic procedures. This product may not be used under the U.S. Food and Drug Administration's (FDA) Emergency Use Authorization (EUA) of the Center for Disease Control and Prevention (CDC) 2019-nCoV Real-Time RT-PCR Diagnostic Panel. The oligonucleotide sequences were designed by the CDC.

Key benefits

- Gold standard quencher: From the trusted inventor and original source of Black Hole Quencher™ (BHQ™) technology referenced in 7 of 8 WHO protocols
- Quality manufacture: All probes and primers are HPLC purified and are manufactured and shipped from a facility entirely separate from positive control production.

Name	Sequence	Catalog Number	Size delivered
2019-nCoV_N1 Forward Primer	GAC CCC AAA ATC AGC GAA AT	LG-NCOV-N1-F-100	100 mmol
		LG-NCOV-N1-F-1000	1000 mnmol
2019-nCoV_N1 Probe	FAM-ACC CCG CAT TAC GTT TGG TGG	LG-NCOV-N1-P-25	25 mmol
	ACC-BHQ1	LG-NCOV-N1-P-250	250 nmol
2019-nCoV_N1 Reverse Primer	TCT GGT TAC TGC CAG TTG AAT CTG	LG-NCOV-N1-R-100	100 mmol
		LG-NCOV-N1-R-1000	1000 mnmol
2019-nCoV_N2 Forward Primer	TTA CAA ACA TTG GCC GCA AA	LG-NCOV-N2-F-100	100 mmol
		LG-NCOV-N2-F-1000	1000 mnmol
2019-nCoV_N2 Probe	FAM-ACA ATT TGC CCC CAG CGC TTC	LG-NCOV-N2-P-25	25 mmol
	AG-BHQ1	LG-NCOV-N2-P-250	250 nmol
2019-nCoV_N2 Reverse Primer	GCG CGA CAT TCC GAA GAA	LG-NCOV-N2-R-100	100 mmol
		LG-NCOV-N2-R-1000	1000 mnmol
2019-nCoV_N3 Forward Primer	GGG AGC CTT GAA TAC ACC AAA A	LG-NCOV-N3-F-100	100 mmol
		LG-NCOV-N3-F-1000	1000 mnmol
2019-nCoV_N3 Probe	FAM-AYC ACA TTG GCA CCC GCA ATC	LG-NCOV-N3-P-25	25 mmol
	CTG-BHQ1	LG-NCOV-N3-P-250	250 nmol
2019-nCoV_N3 Reverse Primer	TGT AGC ACG ATT GCA GCA TTG	LG-NCOV-N3-R-100	100 mmol
		LG-NCOV-N3-R-1000	1000 mnmol
Charite RdRP_SARSr 2019-nCoV FAM-	FAM-	LG-RdRP-SARSr-P2-25	25 nmol
BBQ-650 Probe	CAGGTGGAACCTCATCAGGAGATGC-	LG-RdRP-SARSr-P2-250	250 nmol
	BBQ650	LG-RdRP-SARSr-P2-5	5 nmol
Charite RdRP_SARSr 2019-nCoV FAM-	FAM-	LG-RdRP-SARSr-BHQP2-25	25 nmol
BHQ Probe	ACACTAGCCATCCTTACTGCGCTTCG-	LG-RdRP-SARSr-BHQP2-250	250 nmol
	BHQ1	LG-RdRP-SARSr-BHQP2-5	5 nmol
Charite RdRP_SARSr Forward Primer	GTGARATGGTCATGTGTGGCGG	LG-RdRP-SARSr-F-100	100 nmol
		LG-RdRP-SARSr-F-1000	1000 nmol

Name	Sequence	Catalog Number	Size delivered
		LG-RdRP-SARSr-F-20	20 nmol
Charite RdRP_SARSr Pan Sarbeco FAM-	FAM-	LG-RdRP-SARSr-P1-25	25 nmol
BBQ-650 Probe	CCAGGTGGWACRTCATCMGGTGATGC-	LG-RdRP-SARSr-P1-250	250 nmol
	BBQ650	LG-RdRP-SARSr-P1-5	5 nmol
Charite RdRP_SARSr Pan Sarbeco FAM-	FAM-	LG-RdRP-SARSr-BHQP1-25	25 nmol
BHQ Probe	CCAGGTGGWACRTCATCMGGTGATGC-	LG-RdRP-SARSr-BHQP1-250	250 nmol
	BHQ1	LG-RdRP-SARSr-BHQP1-5	5 nmol
Charite RdRP_SARSr Reverse Primer	CARATGTTAAASACACTATTAGCATA	LG-RdRP-SARSr-R-100	100 mmol
		LG-RdRP-SARSr-R-1000	1000 mnmol
		LG-RdRP-SARSr-R-20	20 nmol
SARS-CoV-2 Variant ValuPanel [del H69- V70]		LG-SCV-DEL69-70-1000	1,000 Reactions
SARS-CoV-2 Variant ValuPanel [E484K]		LG-SCV-E484K-1000	1,000 Reactions
SARS-CoV-2 Variant ValuPanel [E484Q]		LG-SCV-E484Q-1000	1,000 Reactions
SARS-CoV-2 Variant ValuPanel [H655Y]		LG-SCV-H655Y-1000	1,000 Reactions
SARS-CoV-2 Variant ValuPanel [K417N]		LG-SCV-K417N-1000	1,000 Reactions
SARS-CoV-2 Variant ValuPanel [K417T]		LG-SCV-K417T-1000	1,000 Reactions
SARS-CoV-2 Variant ValuPanel [L452R]		LG-SCV-L452R-1000	1,000 Reactions
SARS-CoV-2 Variant ValuPanel [N501Y]		LG-SCV-N501Y-1000	1,000 Reactions
SARS-CoV-2 Variant ValuPanel [P681H] (Version 2)		LG-SCV-P681H-V2-1000	1,000 Reactions
SARS-CoV-2 Variant ValuPanel [P681R]		LG-SCV-P681R-1000	1,000 Reactions
SARS-CoV-2 Variant ValuPanel [T19R]		LG-SCV-T19R-1000	1,000 Reactions
SARS-CoV-2 Variant ValuPanel [T951]		LG-SCV-T95I-1000	1,000 Reactions

Product info

This panel consists of primers and FAM-BHQ probes for use in real-time RT PCR for the detection of the nucleic acid from SARS-CoV-2. The 2019-nCoV ValuPanel Reagents are probes and primers for the following targets:

- SARS-CoV-2 nucleocapsid (N)
- Human RNase P (extraction control)


The oligonucleotide sequences were designed by the CDC as listed on the CDC RUO primer and probe sequence website. All probes are labeled with FAM and BHQ dyes, and are HPLC purified. Please note that this product, the 2019-nCoV ValuPanel Reagents, may not be used under the FDA EUA for the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel.



Kits

Catalog Number	Name	Size	Principle	Sample type	RUO /IVD
BI-VT9200	COVID-19 Viral RNA Extraction Kit (EZ-10 Spin Column)	50 preps	The kit is especially designed for COVID-19 (SARS-CoV-2). It simplifies the isolation of COVID-19 viral RNA from cell-free body fluids with fast spin-column format.	Serum, plasma, cell culture media, milk	RUO
AM-G628	COVID-19 RT-qPCR Rapid Detection Kit	100 rxns	To help researchers in the global fight against the coronavirus, abm has developed an RT-qPCR Rapid Detection Kit for COVID-19 / SARS-CoV-2 that can be used on human respiratory tract specimens.	sputum, naso/oroph aryngeal swabs	RUO
BI-COV-2- RTPCR	SARS-CoV-2 RT-PCR Detection Kit (COVID- 19)	50 rxns	To assist researchers in the battle against COVID-19, our newly developed RT-qPCR kit can be used on human respiratory tract specimens and serves as an ideal molecular diagnostic tool to detect COVID-19 / SARS-CoV-2	Serum	RUO
JE-PCR-703	1copy™ COVID-19 qPCR Kit	100 tests	1copy™ COVID-19 qPCR Kit provides the fast and accurate testing solution for COVID-19, specifically targeting the E gene for beta coronavirus and the RdRp gene for COVID-19 in sputum, nasopharyngeal swab and oropharyngeal swab.	sputum, naso/oroph aryngeal swabs	RUO
500190-SAB	Novel Coronavirus (SARS-CoV-2) Multiplex Real-Time PCR Kit (detection for three genes)	96 tests	This kit provides multiplex detections of SARS-CoV-2's ORF1ab gene, E gene and N gene in a single tube		RUO

SARS-CoV2-Ig



RNA, protein antigens and antibody kinetics, source BioVendor

Kits


Catalog Number	Name	Size	Principle	Sample type	RUO /IVD
AR-K075-H1R	SARS-CoV-2 IgG ELISA Kit	1 plate	The DetectX® SARS-CoV-2 IgG ELISA Kit qualitatively measures COVID-19 (SARS-CoV-2) IgG antibody in human serum. Ready-to-use human positive and negative controls are provided to generate negative (low) and positive (high) optical densities (ODs) for the assay, and all samples should be compared to the OD readings for these two controls.	Serum	RUO
AR-K075-H5R	SARS-CoV-2 IgG ELISA Kit	5 plates	The DetectX® SARS-CoV-2 IgG ELISA Kit qualitatively measures COVID-19 (SARS-CoV-2) IgG antibody in human serum. Ready-to-use human positive and negative controls are provided to generate negative (low) and positive (high) optical densities (ODs) for the assay, and all samples should be compared to the OD readings for these two controls.	Serum	RUO

Catalog Number	Name	Size	Principle	Sample type	RUO /IVD
BE-E88-301	SARS-CoV-2 IgG ELISA Kit (For Research Use Only)	1 x 96 wells	The Bethyl SARS-CoV-2 IgG ELISA is an Enzyme-Linked Immunosorbent Assay (ELISA) intended for semi-quantitative detection of IgG antibodies to SARS-CoV-2 in human serum or plasma collected in Potassium EDTA, Sodium Citrate or Lithium Heparin	Serum, plasma	RUO
BE-E88-302	SARS-CoV-2 IgM ELISA Kit (For Research Use Only)	1 x 96 wells	The Bethyl SARS-CoV-2 IgM ELISA is an Enzyme-Linked Immunosorbent Assay (ELISA) intended for semiquantitative detection of IgM antibodies to SARS-CoV-2 in human serum or plasma collected in Potassium EDTA, Sodium Citrate or Lithium Heparin	Serum, plasma	RUO

SARS-CoV2-lgG/lgM

Kits

Catalog Number	Name	Size	Principle	Sample type	RUO /IVD
EP-D-1002-96	SeroFlash SARS- CoV-2 IgG/IgM ELISA Fast Kit	96 reactions	The SeroFlash™ SARS-CoV-2 IgG/IgM ELISA Fast Kit is a complete set of optimized buffers and reagents to qualitatively detect the IgG and IgM antibodies of the novel coronavirus, SARS-CoV-2, from serum or plasma within 45 min.	serum, plasma	RUO
EP-D-1001R- 025	SeroFlash™ SARS- CoV-2 IgM/IgG Antibody Detection Kit	25 tests	The test is an antibody-based serological method that detects the presence of IgG and IgM antibodies against the SARS-CoV-2 virus in blood samples (serum, plasma, finger prick) RUO	blood	RUO/ IVD
CG2057-SAB	One Step Test for Novel Coronavirus (2019-nCoV) IgM/IgG Antibody (Colloidal Gold)CG2057	25 tests	The test uses mixed recombinant 2019-nCoV nucleocapsid protein (N protein) and spike protein (S protein) both conjugated with colloidal gold and anti-human IgM and IgG antibody coated on different test lines respectively.	serum, plasma, whole blood	IVD
502090-SAB	SARS-CoV-2 IgM/IgG Antibody Rapid Test	20 tests	The Strong Step® SARS-CoV-2 IgM/IgG Test is a rapid immunochromatographic assay for the simultaneous detection of IgM and IgG antibodies to SARS-CoV-2 virus in human whole blood, serum or plasma.	blood, serum, plasma	IVD



Note:Control band fails to appear should be regarded as invalid results.

502090-SAB PROCEDURE:

- 1. Bring the kit components to room temperature before testing. Open the pouch and remove the Card .
- 2. Once opened, the test card must be used immediately
- 3. Label the test card with patients identity.
- 4. Apply $10\mu L$ of serum, plasma or whole blood to the sample well.
- 5. Add 2-3 drops of sample buffer to the sample well.
- 6. At the end of 15 minutes read the results. A strong positive sample may show result earlier.

Note:Result after 15 minutes may not be accurate

Spike

On 26 November 2021, the WHO designated the SARS-CoV-2 variant B.1.1.529 to be the fifth Variant of Concern (VOC) and assigned it the name "Omicron". Of the more than 50 mutations in its genome, at least 32 are in the spike protein with fifteen point mutations in the RBD (Figure 1), including several found in other VOCs linked to increased transmissibility and immune evasion. Like other VOCs, mutations are also found in Omicron's nucleocapsid protein (Figure 2). Omicron is widely distributed and is outcompeting Delta. Though it appears to cause more mild disease, it nevertheless has driven increased hospitalizations.




Figure 1. Spike mutation sites found in Omicron are A67V, Δ 69-70, T95I, G142D/ Δ 143-145, Δ 211/L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493K, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F.




Figure 2. Nucleocapsid protein mutation sites found in Omicron are P13L, Δ 31-33, R203M, G204R, and in Delta are D63G, R203M, G215C, D377Y.

Spike Variant Recombinant Proteins

	Spike	S1	RBD	S2	Nucleocapsid
Omicron Variant	GTX136716-pro				GTX03400-pro
UK Variants	GTX136059-pro	GTX136085-pro	GTX136014-pro	GTX136023-pro	
			GTX136058-pro (with		
			E484K, Kent variant)		
South Africa	GTX136061-pro	GTX136095-pro	GTX136022-pro		
Brazil	GTX136091-pro	GTX136094-pro	GTX136043-pro		
Wild-type	GTX135972-pro	GTX135817-pro	GTX136090-pro	GTX135684-pro	

Antibodies

Ref	Designation	Size	Host	Applications	Туре
GTX632603	SARS-CoV SΔ3 antibody [7G12]	100 μΙ	Mouse	WB, IP	Monoclonal
GTX632603-S	SARS-CoV SΔ3 antibody [7G12]	25 μl	Mouse	WB, IP	Monoclonal
GTX500041	SARS-CoV-2 (COVID19) Spike ELISA Pair [1A9/HL263]	100 μΙ	Mouse Rabbit	ELISA, Sandwich ELISA	Monoclonal
GTX500043	SARS-CoV-2 (COVID19) Spike ELISA Pair [1A9/HL13402]	100 μΙ	Mouse Rabbit	ELISA, Sandwich ELISA	Monoclonal
ARG66739	anti-SARS-CoV / SARS-CoV-2 Spike protein (RBD) antibody [CR3022]	100 μg	Human	ELISA, Neut	Monoclonal
ARG66740	anti-SARS-CoV-2 Spike protein (RBD) antibody [SQab20178]	100 μg	Mouse	ELISA, FACS, ICC/IF, WB	Monoclonal
E-AB-V1006	SARS-COV/SARS-COV-2 Spike RBD Polyoclonal Antibody(2019-nCoV)	100 μΙ	Rabbit	WB, ELISA	Polyclonal
EP-A73680-100	SARS-CoV-2 Spike RBD Nanobody	100 μΙ	Mouse	ELISA, GICA, Neutralization	Recombinant
GTX135385-S	SARS-CoV-2 (COVID-19) Spike RBD antibody	25 μΙ	Rabbit	WB, ICC/IF	Polyclonal
GTX135385	SARS-CoV-2 (COVID-19) Spike RBD antibody	100 μΙ	Rabbit	WB, ICC/IF	Polyclonal
GTX135709	SARS-CoV-2 (COVID-19) Spike RBD antibody	100 μΙ	Rabbit	WB, Neutralizing/Inhibition	Polyclonal
GTX135709-S	SARS-CoV-2 (COVID-19) Spike RBD antibody	25 μΙ	Rabbit	WB, Neutralizing/Inhibition	Polyclonal
GTX635792	SARS-CoV-2 (COVID-19) Spike RBD antibody [HL1003]	100 μΙ	Rabbit	ICC/IF, ELISA, Neutralizing/Inhibition	Monoclonal
GTX635792-S	SARS-CoV-2 (COVID-19) Spike RBD antibody [HL1003]	25 μΙ	Rabbit	ICC/IF, ELISA, Neutralizing/Inhibition	Monoclonal
GTX635866	SARS-CoV-2 (COVID-19) Spike RBD antibody [HL1003-HU]	100 μΙ	Human	ELISA, Neutralizing/Inhibition, Sandwich ELISA	Monoclonal
GTX635866-S	SARS-CoV-2 (COVID-19) Spike RBD antibody [HL1003-HU]	25 μΙ	Human	ELISA, Neutralizing/Inhibition, Sandwich ELISA	Monoclonal
GTX635793	SARS-CoV-2 (COVID-19) Spike RBD antibody [HL1004]	100 μΙ	Rabbit	ICC/IF, ELISA, Neutralizing/Inhibition	Monoclonal
GTX635793-S	SARS-CoV-2 (COVID-19) Spike RBD antibody [HL1004]	25 μΙ	Rabbit	ICC/IF, ELISA, Neutralizing/Inhibition	Monoclonal
GTX635807	SARS-CoV-2 (COVID-19) Spike RBD antibody [HL1014]	100 μΙ	Rabbit	ICC/IF, ELISA	Monoclonal
GTX635807-S	SARS-CoV-2 (COVID-19) Spike RBD antibody [HL1014]	25 μΙ	Rabbit	ICC/IF, ELISA	Monoclonal
GTX635692-S	SARS-CoV-2 (COVID-19) Spike RBD antibody [HL257]	25 μΙ	Rabbit	WB, ICC/IF, ELISA	Monoclonal
GTX635692	SARS-CoV-2 (COVID-19) Spike RBD antibody [HL257]	100 μΙ	Rabbit	WB, ICC/IF, ELISA	Monoclonal

Ref	Designation	Size	Host	Applications	Туре
GTX636042-S	SARS-CoV-2 (COVID-19) Spike	25 μΙ	Mouse	WB, ELISA, Sandwich	Monoclonal
	RBD antibody [GT5449]			ELISA	
GTX636042	SARS-CoV-2 (COVID-19) Spike	100 μΙ	Mouse	WB, ELISA, Sandwich	Monoclonal
	RBD antibody [GT5449]	•		ELISA	
0	SARS-CoV-2 (COVID-19) Spike	25 μΙ	Rabbit	Neutralizing/Inhibition	Monoclonal
GTX635791-S	RBD antibody [HL1002]	-		_	
0	SARS-CoV-2 (COVID-19) Spike	100 μΙ	Rabbit	Neutralizing/Inhibition	Monoclonal
GTX635791	RBD antibody [HL1002]				
GTX134864	MERS-CoV S1 protein antibody	100 μΙ	Rabbit	WB	Polyclonal
GTX134864-S	MERS-CoV S1 protein antibody	25 μΙ	Rabbit	WB	Polyclonal
GTX134875	MERS-CoV S1 protein antibody	100 μΙ	Rabbit	WB	Polyclonal
GTX134875-S	MERS-CoV S1 protein antibody	25 μΙ	Rabbit	WB	Polyclonal
EP-A73672-100	SARS-CoV-2 S Recombinant	100 μl	Mouse	ELISA, GICA,	Recombinant
	Antibody	•		Neutralization	
EP-A73675-050	SARS-CoV-2 S Recombinant	50 μl	Mouse	ELISA	Recombinant
	Antibody, Biotin Conjugated	·			
EP-A73675-100	SARS-CoV-2 S Recombinant	100 μΙ	Mouse	ELISA	Recombinant
	Antibody, Biotin Conjugated				
EP-A73674-050	SARS-CoV-2 S Recombinant	50 μl	Mouse	ELISA	Recombinant
	Antibody, FITC Conjugated				
EP-A73674-100	SARS-CoV-2 S Recombinant	100 μΙ	Mouse	ELISA	Recombinant
	Antibody, FITC Conjugated				
EP-A73673-050	SARS-CoV-2 S Recombinant	50 μl	Mouse	ELISA	Recombinant
	Antibody, HRP Conjugated				
EP-A73673-100	SARS-CoV-2 S Recombinant	100 μΙ	Mouse	ELISA	Recombinant
	Antibody, HRP Conjugated				
E-AB-V1005	SARS-COV/SARS-COV-2 Spike	100 μΙ	Rabbit	IF,ELISA	Monoclonal
	S1 Monoclonal				
	Antibody(2019-nCoV)				
GTX135384-S	SARS-CoV-2 (COVID-19) Spike	25 μΙ	Rabbit	WB, ICC/IF	Polyclonal
0=1/40=004	S1 antibody	100			
GTX135384	SARS-CoV-2 (COVID-19) Spike	100 μΙ	Rabbit	WB, ICC/IF	Polyclonal
CTVC25700.C	S1 antibody	25	N.4	NA/D	N.4
GTX635708-S	SARS-CoV-2 (COVID-19) Spike	25 μΙ	Mouse	WB	Monoclonal
CTV62F709	S1 antibody [GT263] SARS-CoV-2 (COVID-19) Spike	100	Mausa	WB	Monoclonal
GTX635708	S1 antibody [GT263]	100 μΙ	Mouse	VVD	Monocional
GTX635656	SARS-CoV-2 (COVID-19) Spike	100 μΙ	Rabbit	WB, ICC/IF, ELISA,	Monoclonal
G1X033030	S1 antibody [HL1]	100 μι	Nabbit	sELISA	Wioriocional
GTX635656-S	SARS-CoV-2 (COVID-19) Spike	25 μΙ	Rabbit	WB, ICC/IF, ELISA,	Monoclonal
31/1033030 3	S1 antibody [HL1]	25 μι	MADDIC	sELISA	
GTX635671	SARS-CoV-2 (COVID-19) Spike	100 μΙ	Rabbit	WB, ICC/IF, ELISA	Monoclonal
,	S1 antibody [HL134]	J F N.		_, , ,	
GTX635671-S	SARS-CoV-2 (COVID-19) Spike	25 μΙ	Rabbit	WB, ICC/IF, ELISA	Monoclonal
	S1 antibody [HL134]	'		, , , -	
GTX635713-S	SARS-CoV-2 (COVID-19) Spike	25 μΙ	Rabbit	WB, ELISA	Monoclonal
	S1 antibody [HL13402]				
GTX635713	SARS-CoV-2 (COVID-19) Spike	100 μΙ	Rabbit	WB, ELISA	Monoclonal
	S1 antibody [HL13402]				

Ref	Designation	Size	Host	Applications	Туре
GTX635672	SARS-CoV-2 (COVID-19) Spike	100 μl	Rabbit	WB, ICC/IF, ELISA	Monoclonal
	S1 antibody [HL263]	•			
GTX635672-S	SARS-CoV-2 (COVID-19) Spike	25 μΙ	Rabbit	WB, ICC/IF, ELISA	Monoclonal
	S1 antibody [HL263]				
GTX635654	SARS-CoV-2 (COVID-19) Spike	100 μΙ	Rabbit	WB, ICC/IF, ELISA,	Monoclonal
	S1 antibody [HL6]			sELISA	
GTX635654-S	SARS-CoV-2 (COVID-19) Spike	25 μΙ	Rabbit	WB, ICC/IF, ELISA,	Monoclonal
	S1 antibody [HL6]			sELISA	
21803-1-SAB	Anti-2019-nCoV S1 mAb (5D9)	50 μg	Human	Diagnostic	Monoclonal
21803-2-SAB	Anti-2019-nCoV S1 mAb (5D9)	1 mg	Human	Diagnostic	Monoclonal
GTX135386-S	SARS-CoV-2 (COVID-19) Spike	25 μΙ	Rabbit	ICC/IF, ELISA, sELISA	Polyclonal
	S2 / S2' antibody				
GTX135386	SARS-CoV-2 (COVID-19) Spike	100 µl	Rabbit	ICC/IF, ELISA, sELISA	Polyclonal
	S2 / S2' antibody				
GTX635911-S	SARS-CoV-2 (COVID-19) Spike	25 μΙ	Rabbit	WB, ICC/IF, ELISA,	Monoclonal
	S2 / S2' antibody [HL1039]	•		Sandwich ELISA	
GTX635911	SARS-CoV-2 (COVID-19) Spike	100 μΙ	Rabbit	WB, ICC/IF, ELISA,	Monoclonal
CTVC25 CO2 C	S2 / S2' antibody [HL1039]	25 1	5 11.0	Sandwich ELISA	
GTX635693-S	SARS-CoV-2 (COVID-19) Spike	25 μΙ	Rabbit	WB, ICC/IF	Monoclonal
CTVC2FC02	S2 antibody [HL237]	100l	Dabbi+	WD ICC/IE	Managlanal
GTX635693	SARS-CoV-2 (COVID-19) Spike S2 antibody [HL237]	100 μΙ	Rabbit	WB, ICC/IF	Monoclonal
GTX635910-S	SARS-CoV-2 (COVID-19) Spike	25 μΙ	Rabbit	WB, ICC/IF, ELISA	Monoclonal
G1X033310-3	S2 antibody [HL1038]	25 μι	Nabbit	WD, ICC/II , LLISA	Wioriocional
GTX635910	SARS-CoV-2 (COVID-19) Spike	100 μΙ	Rabbit	WB, ICC/IF, ELISA	Monoclonal
01/100001	S2 antibody [HL1038]	100 p.	Nabbit	113) 100/11 / 22.57 (Wiene en
GTX632604-S	SARS-CoV/SARS-CoV-2	25 μΙ	Mouse	WB, ICC/IF, IHC-P,	Monoclonal
	(COVID-19) Spike antibody	•		FACS, IP, ELISA,	
	[1A9]			Sandwich ELISA, IHC-P	
				(cell pellet)	
GTX632604	SARS-CoV/SARS-CoV-2	100 μΙ	Mouse	WB, ICC/IF, IHC-P,	Monoclonal
	(COVID-19) Spike antibody			FACS, IP, ELISA,	
	[1A9]			Sandwich ELISA, IHC-P	
		_		(cell pellet)	
GTX135356-S	SARS-CoV-2 (COVID-19) Spike	25 μΙ	Rabbit	WB, ICC/IF, ELISA,	Polyclonal
	antibody			Sandwich ELISA, IHC-P	
CTV12F2FC	SARS COV 2 (COVID 40) Colle	100!	Dale!+	(cell pellet)	Dalvela::-!
GTX135356	SARS-CoV-2 (COVID-19) Spike	100 μΙ	Rabbit	WB, ICC/IF, ELISA, Sandwich ELISA, IHC-P	Polyclonal
	antibody			(cell pellet)	
GTX135360-S	SARS-CoV-2 (COVID-19) Spike	25 μΙ	Rabbit	WB, ICC/IF, ELISA,	Polyclonal
G1VT33300-3	antibody	25 μι	Nabbit	Sandwich ELISA	roryclonal
GTX135360	SARS-CoV-2 (COVID-19) Spike	100 μΙ	Rabbit	WB, ICC/IF, ELISA,	Polyclonal
317133300	antibody	100 μι	Nabbit	Sandwich ELISA	. Oryclonal
GTX01555	SARS-CoV/SARS-CoV-2	100 μg	Human	ELISA,	Monoclonal
G1/(01333	(COVID-19) Spike antibody	100 μg	Halliali	Neutralizing/Inhibition	ivioliocional
	[CR3022]			Treation Line / Initialition	
	[]				

Ref	Designation	Size	Host	Applications	Туре
GTX01556	SARS-CoV/SARS-CoV-2 (COVID-19) Spike antibody [CR3022-RB]	100 μg	Rabbit	ELISA, Neutralizing/Inhibition	Monoclonal

^{• :} Omicron tested. Recombinant protein derived from different SARS-CoV-2 variants were assayed by ELISA using the specified GeneTex monoclonal antibodies.

Antibody Pairs

Ref	Designation Size		Host	Applications	Туре
GTX500046	SARS-CoV-2 (COVID-19) Spike RBD ELISA Pair [HL1014 / HL1003]	50 μΙ	Rabbit	ELISA	Polclonal

FFPE blocks

Ref	Designation	Application
GTX435640	SARS-CoV-2 (COVID-19) Spike FFPE Cell Pellet Block	IHC-P
GTX435643	SARS-CoV-2 (COVID-19) Spike S1 FFPE Cell Pellet Block	IHC-P
GTX435644	SARS-CoV-2 (COVID-19) Spike S2 FFPE Cell Pellet Block	IHC-P

Kits

Catalog Number	Name	Size	Principle	Sample type	RUO /IVD
CB-VPK-5155	SARS-CoV-2 Spike Protein S1 ELISA Kit	96T	Measures the spike protein (S1 subunit) of SARS-CoV-2 Detects concentrations as low as 31.3ng/ml of the spike protein S1 Recombinant SARS-CoV-2 spike protein S1 standard included	Viral supernatant	RUO
CB-VPK-5155-5	SARS-CoV-2 Spike Protein S1 ELISA Kit	5 X 96T	Measures the spike protein (S1 subunit) of SARS-CoV-2 Detects concentrations as low as 31.3ng/ml of the spike protein S1 Recombinant SARS-CoV-2 spike protein S1 standard included	Viral supernatant	RUO

Overexpression Lysates

Ref	Designation	Application
GTX535664	SARS-CoV-2 (COVID-19) Spike overexpression 293T whole cell lysate	WB, ELISA
GTX535663	SARS-CoV-2 (COVID-19) Spike S1 overexpression 293T whole cell lysate	WB
GTX535668	SARS-CoV Spike overexpression 293T whole cell lysate	WB, ELISA

Proteins

Ref	Designation	Size	Expression system	Tag
AP89515-1-SAB	Recombinant 2019-nCoV S Protein RBD-SD1	50 μg	Mammalian expression system	His-Tag
AP89515-2-SAB	Recombinant 2019-nCoV S Protein RBD-SD1	500 μg	Mammalian expression system	His-Tag
AP89515-3-SAB	Recombinant 2019-nCoV S Protein RBD-SD1	1 mg	Mammalian expression system	His-Tag
AP89514-1-SAB	Recombinant 2019-nCoV S Protein RBD-SD1 (C-mFC)	50 μg	Mammalian expression system	mFC Tag
AP89514-2-SAB	Recombinant 2019-nCoV S Protein RBD-SD1 (C-mFC)	500 μg	Mammalian expression system	mFC Tag
AP89514-3-SAB	Recombinant 2019-nCoV S Protein RBD-SD1 (C-mFC)	1 mg	Mammalian expression system	mFC Tag
AP89516-1-SAB	Recombinant 2019-nCoV S1 Protein	50 μg	Mammalian	
AP89516-2-SAB	Recombinant 2019-nCoV S1 Protein	500μg	Mammalian	
AP89516-3-SAB	Recombinant 2019-nCoV S1 Protein	1mg	Mammalian	
PKSR030481	Recombinant 2019-nCoV S1 Protein	1 mg	Human Cells	
E-PKSR030483	Recombinant 2019-nCoV S1 Protein (CTD, His Tag)	1 mg	Human Cells	N-8His- Flag
E-PKSR030480	Recombinant 2019-nCoV S1 Protein (Fc Tag)	1 mg	Human Cells	C-Fc
E-PKSR030502	Recombinant 2019-nCoV S1 Protein (Fc Tag)	100 μg	HEK293 Cells	C-Fc
E-PKSR030482	Recombinant 2019-nCoV S1 Protein (His Tag)	1 mg	Human Cells	C-6His
E-PKSR030503	Recombinant 2019-nCoV S1 Protein (His Tag)	100 μg	HEK293 Cells	C-6His
E-PKSR030479	Recombinant 2019-nCoV S1 Protein (mFc Tag)	1 mg	Human Cells	C-mFc
E-PKSR030504	Recombinant 2019-nCoV S1 Protein (mFc Tag)	100 μg	HEK293 Cells	C-mFc
AL-RP01260LQ	Recombinant 2019-nCoV S1+S2 ECD (S-ECD) Protein with His tag	100 μg	HEK293T	C-6His
AL-RP01260MT	Recombinant 2019-nCoV S1+S2 ECD (S-ECD) Protein with His tag	100 μg	HEK293T	C-6His
E-PKSR030498	Recombinant 2019-nCoV S1+S2 Protein (ECD, His Tag)	100 μg	Baculovirus- Insect Cells	C-6His
E-PKSR030505	Recombinant 2019-nCoV S2 Protein (ECD, His Tag)	100 μg	Baculovirus- Insect Cells	C-6His

Ref	Designation	Size	Expression system	Tag
E-PKSR030491	Recombinant 2019-nCoV S2 Protein (Fc Tag)	1 mg	Human Cells	C-Fc
E-PKSR030484	Recombinant 2019-nCoV Spike Protein (NTD, His Tag)	1 mg	Human Cells	C-6His
E-PKSR030475	Recombinant 2019-nCoV Spike Protein (RBD, His Tag)	1 mg	Human Cells	C-6His
E-PKSR030499	Recombinant 2019-nCoV Spike Protein (RBD, His Tag)	100 μg	Baculovirus- Insect Cells	C-6His
E-PKSR030474	Recombinant 2019-nCoV Spike Protein (RBD, mFc Tag)	1 mg	Human Cells	C-mFc
E-PKSR030500	Recombinant 2019-nCoV Spike Protein (RBD, mFc Tag)	100 μg	HEK293 Cells	C-mFc
E-PKSR030477	Recombinant 2019-nCoV Spike Protein (RBD-SD1, His Tag)	1 mg	Human Cells	C-6His
E-PKSR030476	Recombinant 2019-nCoV Spike Protein (RBD-SD1, mFc Tag)	1 mg	Human Cells	C-mFC
E-PKSR030501	Recombinant 2019-nCoV Spike Protein, Biotinylated (RBD, His Tag)	20 μg	Baculovirus- Insect Cells	C-6His
E-PKSR030478	Recombinant 2019-nCoV Spike Protein, Biotinylated (RBD-SD1, Avi-His Tag)	1 mg	Human Cells	C-Avi-6His
AL-RP01258	Recombinant 2019-nCoV Spike RBD Protein with His tag	100 μg	HEK293T	C-6His
AL-RP01271	Recombinant 2019-nCoV Spike RBD Protein with mFc tag	100 μg	HEK293T	C-mFc
AL-RP01259	Recombinant 2019-nCoV Spike S1 Protein with Fc and His tag	100 μg	HEK293T	C-6His
AL-RP01261	Recombinant 2019-nCoV Spike S1 Protein with His tag and Avi	100 μg	HEK293T	C-Avi-6His
AL-RP01267	Recombinant 2019-nCoV Spike S2 ECD Protein with His tag	100 μg	HEK293T	C-6His
EP-E80018-1	Recombinant Novel Coronavirus Spike Glycoprotein(S), Partial	20 μg	Mammalian cell	
EP-E80018-2	Recombinant Novel Coronavirus Spike Glycoprotein(S), Partial	100 μg	Mammalian cell	
EP-E80018-3	Recombinant Novel Coronavirus Spike Glycoprotein(S), Partial	1 mg	Mammalian cell	
AV-OPSN00001	Recombinant SARS-CoV 2 Spike Protein	100 μg	E. coli	
EP-E80002-1	Recombinant SARS-CoV-2 S1+S2 ECD (S-ECD) Protein with His-Tag	100 μg	HEK293 cells	His-Tag
EP-E80000-1	Recombinant SARS-CoV-2 Spike RBD Protein with His-Tag	100 μg	HEK293 cells	His-Tag
EP-E80015-1	Recombinant SARS-CoV-2 Spike RBD Protein with His-Tag	100 μg	HEK293 cells	His-Tag
EP-E80011-1	Recombinant SARS-CoV-2 Spike RBD Protein with mFc Tag	100 μg	HEK293 cells	mFC Tag
EP-E80001-1	Recombinant SARS-CoV-2 Spike S1 Protein with hFc and His-Tag	100 μg	HEK293 cells	hFc and His Tag
EP-E80003-1	Recombinant SARS-CoV-2 Spike S1 Protein with His and Avi Tag	100 μg	HEK293 cells	His and Avi Tag
EP-E80004-1	Recombinant SARS-CoV-2 Spike S1 Protein with His-Tag	100 μg	HEK293 cells	His-Tag

Ref	Designation	Size	Expression system	Tag
EP-E80007-1	Recombinant SARS-CoV-2 Spike S1 Protein with His-Tag	100 μg	HEK293 cells	His-Tag
CC-RPX273Ge01-10UG	Recombinant Spike Protein (SP)	10 μg	E. coli	His-Tag
CC-RPX273Ge01-1MG	Recombinant Spike Protein (SP)	1 mg	E. coli	His-Tag
CC-RPX273Ge01-200UG	Recombinant Spike Protein (SP)	200 μg	E. coli	His-Tag
CC-RPX273Ge01-50UG	Recombinant Spike Protein (SP)	50 μg	E. coli	His-Tag
CC-RPX273Ge02-10UG	Recombinant Spike Protein (SP)	10 μg	E. coli	His-Tag
CC-RPX273Ge02-1MG	Recombinant Spike Protein (SP)	1 mg	E. coli	His-Tag
CC-RPX273Ge02-200UG	Recombinant Spike Protein (SP)	200 μg	E. coli	His-Tag
CC-RPX273Ge02-50UG	Recombinant Spike Protein (SP)	50 μg	E. coli	His-Tag
CC-RPX273Ge03-10UG	Recombinant Spike Protein (SP)	10 μg	E. coli	His-Tag
CC-RPX273Ge03-1MG	Recombinant Spike Protein (SP)	1 mg	E. coli	His-Tag
CC-RPX273Ge03-200UG	Recombinant Spike Protein (SP)	200 μg	E. coli	His-Tag
CC-RPX273Ge03-50UG	Recombinant Spike Protein (SP)	50 μg	E. coli	His-Tag
AP89521-SAB	SARS-CoV-2 (2019-nCoV) Spike Protein (S2 ECD)	100 μg	Baculovirus- Insect Cells	His-Tag
GTX136059-pro	SARS-CoV-2 (COVID-19) Spike (del69-70, del144,N501Y,A570D,D614G,) (ECD) Protein, His tag (active)	0,1 mg	HEK293	His-Tag
GTX135972-pro	SARS-CoV-2 (COVID-19) Spike (ECD) protein, His tag (active)	0,1 mg	HEK293	His-Tag
GTX137880-pro NEW!	SARS-CoV-2 (COVID-19) Spike (ECD) Protein, Omicron / BF.7 variant, His tag	100 μg	HEK293 cells	His Tag
GTX137881-pro NEW!	SARS-CoV-2 (COVID-19) Spike (ECD) Protein, Omicron / BQ.1 variant, His tag	100 μg	HEK293 cells	His Tag
GTX136061-pro	SARS-CoV-2 (COVID-19) Spike (L18F, K417N, E484K, N501Y) (ECD) Protein, His tag (active)	0,1 mg	HEK293	
GTX136091-pro	SARS-CoV-2 (COVID-19) Spike (L18F, K417T, E484K, N501Y, D614G, V987P) (ECD), His tag (active)	0,1 mg	HEK293	His-Tag
GTX02774-pro	SARS-CoV-2 (COVID-19) Spike Protein, His tag (Active)	100 μg	HEK293	His-Tag
GTX136058-pro	SARS-CoV-2 (COVID-19) Spike RBD (E484K, N501Y Mutant) protein, His tag (active)	0,1 mg	HEK293	His tag
GTX136022-pro	SARS-CoV-2 (COVID-19) Spike RBD (K417N, E484K, N501Y Mutant) protein, His tag (active)	100 μg	HEK293	His-Tag
GTX136014-pro	SARS-CoV-2 (COVID-19) Spike RBD (N501Y Mutant) protein, His tag (active)	100 μg	HEK293	His-Tag
GTX01546-pro	SARS-CoV-2 (COVID-19) Spike RBD protein, His tag (active)	100 μg	HEK293	His-Tag
GTX136090-pro	SARS-CoV-2 (COVID-19) Spike RBD protein, His tag (active)	0,1 mg	HEK293	His tag
GTX137878-pro NEW !	SARS-CoV-2 (COVID-19) Spike RBD Protein, Omicron / BF.7 variant, His tag	100 μg	HEK293 cells	His Tag
GTX137879-pro NEW!	SARS-CoV-2 (COVID-19) Spike RBD Protein, Omicron / BQ.1 variant, His tag	100 μg	HEK293 cells	His Tag
GTX136085-pro	SARS-CoV-2 (COVID-19) Spike S1 (del69-70, del44, N501Y, A570D, D614G) Protein, His tag (active)	100 μg	HEK293	His-Tag

Ref	Designation	Size	Expression system	Tag
GTX136095-pro	SARS-CoV-2 (COVID-19) Spike S1 (L18F, D80A, R246I, K417N, E484K, N501Y, D614G), His tag (active)	100 μg	HEK293	His-Tag
GTX136094-pro	SARS-CoV-2 (COVID-19) Spike S1 (L18F, R190S, K417T, E484K, N501Y, D614G, H655Y), His tag (active)	100 μg	HEK293	His-Tag
GTX135817-pro	SARS-CoV-2 (COVID-19) Spike S1 protein, (active)	100 μg	HEK293	His tag
GTX01548-pro	SARS-CoV-2 (COVID-19) Spike S1 protein, His and Avi tag (active)	100 μg	HEK293	His-Avi Tag
GTX01554-pro	SARS-CoV-2 (COVID-19) Spike S1 protein, His tag (active)	100 μg	HEK293	His-Tag
GTX01559-pro	SARS-CoV-2 (COVID-19) Spike S2 (ECD) protein, human IgG Fc tag	100 μg	HEK293	FC Tag
GTX135684-pro	SARS-CoV-2 (COVID-19) Spike S2 (ECD) protein, mouse IgG Fc tag	100 μg	HEK293	FC Tag
GTX136023-pro	SARS-CoV-2 (COVID-19) Spike S2 (T716I, S982A, D1118H Mutant) (ECD) protein, His tag	100 μg	HEK293	His-Tag
ARG70219	SARS-CoV-2 Spike recombinant protein (RBD)	100 μg	E. coli	His-Tag
ARG70218	SARS-CoV-2 Spike recombinant protein (S1 Subunit)	100 μg	E. coli	His-Tag
EP-E80020-1	SARS-CoV-2 Spike S1 (13-665) Protein, Fc Fusion, Avi-tag	100 μg	HEK293 cells	Avi-Tag
EP-E80020-2	SARS-CoV-2 Spike S1 (13-665) Protein, Fc Fusion, Avi-tag	1 mg	HEK293 cells	Avi-Tag
EP-E80021-1	SARS-CoV-2 Spike S1 (16-685) Protein, Avi-His-tag	100 μg	HEK293 cells	Avi and His Tag
EP-E80021-2	SARS-CoV-2 Spike S1 (16-685) Protein, Avi-His-tag	1 mg	HEK293 cells	Avi and His Tag
EP-E80022-1	SARS-CoV-2 Spike S1 (16-685) Protein, Fc Fusion, Avi-tag	100 μg	HEK293 cells	Avi-Tag
EP-E80022-2	SARS-CoV-2 Spike S1 (16-685) Protein, Fc Fusion, Avi-tag	1 mg	HEK293 cells	Avi-Tag
EP-E80023-1	SARS-CoV-2 Spike S1 RBD (V367F) Protein, Avi-Histag	100 μg	HEK293 cells	Avi and His Tag
EP-E80023-2	SARS-CoV-2 Spike S1 RBD (V367F) Protein, Avi-Histag	1 mg	HEK293 cells	Avi and His Tag
EP-E80024-1	SARS-CoV-2 Spike S1 RBD Protein, Avi-His-tag	100 μg	HEK293 cells	Avi and His Tag
EP-E80024-2	SARS-CoV-2 Spike S1 RBD Protein, Avi-His-tag	1 mg	HEK293 cells	Avi and His Tag
EP-E80025-1	SARS-CoV-2 Spike S1 RBD Protein, Human Fc- Fusion, Avi-Tag	100 μg	HEK293 cells	Avi-Tag
EP-E80025-2	SARS-CoV-2 Spike S1 RBD Protein, Human Fc- Fusion, Avi-Tag	1 mg	HEK293 cells	Avi-Tag
EP-E80026-1	SARS-CoV-2 Spike S1 RBD Protein, Mouse Fc- fusion	20 μg	HEK293 cells	
EP-E80026-2	SARS-CoV-2 Spike S1 RBD Protein, Mouse Fc- fusion	50 μg	HEK293 cells	
PR-AG30689	Spike protein Fusion Protein	50 μg	E. coli	GST

Supplementary tools

3D Cell Culture


Communication between multiple 3D structures.

3D CoSeedis™ enables cell-to-cell and organ-to-organ. To do so, opens the door to an amazing complexity of what can be mimicked accurately in *in vitro* cell culture models with the help of 3D CoSeedis™. Yet, the setup of those models remains easy to handle, reproducible and, consequently and most importantly, predictive.

It combines:

- 3D CoSeedis™ 3D conical aggregates with contact feeders
- 3D CoSeedis[™] 3D conical aggregates w/o feeders
- Distance co-cultured feeders in 2D
- Suspension cells
- And a biological agent (e.g. drug compound, infections particle, else).

Predictive complex disease modelling with 3D CoSeedis™



Complex cell-to-cell and organ-to-organ communication model to investigate systemic diseases. Note: the individual 3D structure can be combined at leisure to come up with a model that reflects best the situation *in vivo*

In such a setup, it is possible to monitor the interaction and effect of:

- Cells in direct contact with each other (e.g. intra-organic communication)
- Cells from different organic origin (e.g. inter-organic communication)
- Suspension cells with organs of different origin (e.g. blood cells)
- And the response or reaction of the system to biologically active agents such as drug compounds, infectious particles, toxins, etc.

Despite the achieved complexity, the individual components and cells of the system can easily be analysed since the setup is all modular and can be separated for in-depth analysis via:

- Immunohistochemistry
- Immunofluorescence
- Protein/DNA/RNA profiling
- Catabolite content in medium
- In situ hybridization
- Whole-mount staining methods
- Volumetric analysis
- And many more....

Ref	Designation	Size
AC-C200-6	3D CoSeedis™ Chip200 6 chips (3D CoSeedis™ Chip2000) for 200 organoids each in beaker containing 1xPBS w/o Mg2+/Ca2+, compatible with 6-well plates	6 Chips
AC-C880-6	3D CoSeedis™ Chip880 6 chips (3D CoSeedis™ Chip880) for 880 organoids each in beacker containing 1xPBS w/o Mg2+/Ca2+, compatible with 6-well plates	6 Chips
AC-C680-6	3D CoSeedis™ Chip680 6 chips (3D CoSeedis™ Chip680) for 680 organoids each in beacker containing 1xPBS w/o Mg2+/Ca2+, compatible with 24-well plates	6 Chips
AC-C680-12	3D CoSeedis™ Chip680 12 chips (3D CoSeedis™ Chip680) for 680 organoids each in beacker containing 1xPBS w/o Mg2+/Ca2+, compatible with 24- well plates	2 X 6 Chips
AC-SPT-V0919	Spatula for 3D CoSeedis™C680 for matrix handling, sterile.	1 PC
AC-SPT-V1117	Spatula for 3D CoSeedis™C200/880 for matrix handling, sterile.	1 PC

Antibodies

Ref	Designation	Size	Host	Applications	Туре
GTX134880-S	MERS-CoV ORF4a antibody	25 μΙ	Rabbit	WB	Polyclonal
GTX134869	MERS-CoV ORF4a antibody	100 μΙ	Rabbit	WB	Polyclonal
GTX134880	MERS-CoV ORF4a antibody	100 μΙ	Rabbit	WB	Polyclonal
GTX134870-S	MERS-CoV ORF4b antibody	25 μΙ	Rabbit	WB	Polyclonal
GTX134870	MERS-CoV ORF4b antibody	100 μΙ	Rabbit	WB	Polyclonal
GTX632602-S	SARS-CoV / SARS-CoV-2 (COVID- 19) ORF7a antibody [3C9]	25 μΙ	Mouse	WB, ICC/IF	Monoclonal
GTX632602	SARS-CoV / SARS-CoV-2 (COVID- 19) ORF7a antibody [3C9]	100 μΙ	Mouse	WB, ICC/IF	Monoclonal
GTX632696-S	SARS-CoV NSP8 antibody [5A10]	25 μΙ	Mouse	WB	Monoclonal
GTX632696	SARS-CoV NSP8 antibody [5A10]	100 μΙ	Mouse	WB	Monoclonal
GTX135612-S	SARS-CoV-2 (COVID-19) nsp1 antibody	25 μΙ	Rabbit	WB	Polyclonal
GTX135586-S	SARS-CoV-2 (COVID-19) nsp1 antibody	25 μΙ	Rabbit	WB	Polyclonal
GTX135612	SARS-CoV-2 (COVID-19) nsp1 antibody	100 μΙ	Rabbit	WB	Polyclonal
GTX135586	SARS-CoV-2 (COVID-19) nsp1 antibody	100 μΙ	Rabbit	WB	Polyclonal
GTX135734-S	SARS-CoV-2 (COVID-19) nsp10 antibody	25 μΙ	Rabbit	WB	Polyclonal
GTX135733	SARS-CoV-2 (COVID-19) nsp10 antibody	100 μΙ	Rabbit	WB	Polyclonal
GTX135734	SARS-CoV-2 (COVID-19) nsp10 antibody	100 μΙ	Rabbit	WB	Polyclonal
GTX135742-S	SARS-CoV-2 (COVID-19) nsp11 antibody	25 μΙ	Rabbit	WB	Polyclonal
GTX135742	SARS-CoV-2 (COVID-19) nsp11 antibody	100 μΙ	Rabbit	WB	Polyclonal
GTX135737-S	SARS-CoV-2 (COVID-19) nsp15 antibody	25 μΙ	Rabbit	WB	Polyclonal
GTX135737	SARS-CoV-2 (COVID-19) nsp15 antibody	100 μΙ	Rabbit	WB	Polyclonal
GTX135717-S	SARS-CoV-2 (COVID-19) nsp2 antibody	25 μΙ	Rabbit	WB	Polyclonal
GTX135717	SARS-CoV-2 (COVID-19) nsp2 antibody	100 μΙ	Rabbit	WB	Polyclonal
GTX135730-S	SARS-CoV-2 (COVID-19) nsp8 antibody	25 μΙ	Rabbit	WB	Polyclonal
GTX135730	SARS-CoV-2 (COVID-19) nsp8 antibody	100 μΙ	Rabbit	WB	Polyclonal
GTX135732-S	SARS-CoV-2 (COVID-19) nsp9 antibody	25 μΙ	Rabbit	WB	Polyclonal
GTX135732	SARS-CoV-2 (COVID-19) nsp9 antibody	100 μΙ	Rabbit	WB	Polyclonal
AL-A20234	SARS-CoV-2 ORF3A antibody	20 μΙ	Rabbit	WB	Polyclonal

Ref	Designation	Size	Host	Applications	Туре
AL-A20234	SARS-CoV-2 ORF3A antibody	100 μΙ	Rabbit	WB	Polyclonal
AL-A20324	SARS-CoV-2 ORF6	20 μΙ	Rabbit	WB	Polyclonal
AL-A20324	SARS-CoV-2 ORF6	100 μΙ	Rabbit	WB	Polyclonal
GTX135591-S	SARS-CoV-2 (COVID-19) ORF8 antibody	25 μΙ	Rabbit	WB	Polyclonal
GTX135591	SARS-CoV-2 (COVID-19) ORF8 antibody	100 μΙ	Rabbit	WB	Polyclonal
GTX135614-S	SARS-CoV-2 (COVID-19) PLpro (nsp3) antibody	25 μΙ	Rabbit	WB	Polyclonal
GTX135589-S	SARS-CoV-2 (COVID-19) PLpro (nsp3) antibody	25 μΙ	Rabbit	WB, ICC/IF	Polyclonal
GTX135589	SARS-CoV-2 (COVID-19) PLpro (nsp3) antibody	100 μΙ	Rabbit	WB, ICC/IF	Polyclonal
GTX135614	SARS-CoV-2 (COVID-19) PLpro (nsp3) antibody	100 μΙ	Rabbit	WB	Polyclonal
GTX135467-S	SARS-CoV-2 (COVID-19) RdRp (nsp12) antibody	25 μΙ	Rabbit	WB	Polyclonal
GTX135469-S	SARS-CoV-2 (COVID-19) RdRp (nsp12) antibody	25 μΙ	Rabbit	WB	Polyclonal
GTX135467	SARS-CoV-2 (COVID-19) RdRp (nsp12) antibody	100 μΙ	Rabbit	WB	Polyclonal
GTX135469	SARS-CoV-2 (COVID-19) RdRp (nsp12) antibody	100 μΙ	Rabbit	WB	Polyclonal
AL-A20283-20 μl	SARS-CoV-2 NSP16 antibody	20 μΙ	Rabbit	WB, IP, IF	Polyclonal
AL-A20283-100 μl	SARS-CoV-2 NSP16 antibody	100 μΙ	Rabbit	WB, IP, IF	Polyclonal

Inhibitors

Référence	Designation	Size	Information
AB-M6222-5mg	Adalimumab	5 mg	Adalimumab is the first fully human, recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha, MW: 144.19 KD.
AB-M5053-10mg	Arbidol hydrochloride	10 mg	Arbidol hydrochloride is an broad-spectrum antiviral chemical agent which can inhibit cell entry of enveloped viruses by blocking viral fusion with host cell membrane.
AB-M5053-50mg	Arbidol hydrochloride	50 mg	Arbidol hydrochloride is an broad-spectrum antiviral chemical agent which can inhibit cell entry of enveloped viruses by blocking viral fusion with host cell membrane.
AB-M5053-100mg	Arbidol hydrochloride	100 mg	Arbidol hydrochloride is an broad-spectrum antiviral chemical agent which can inhibit cell entry of enveloped viruses by blocking viral fusion with host cell membrane.
SE-S3079-10mg	Atovaquone	10 mg	Atovaquone is a medication used to treat or prevent for pneumocystis pneumonia, toxoplasmosis, malaria, and babesia.
SE-S3079-50mg	Atovaquone	50 mg	Atovaquone is a medication used to treat or prevent for pneumocystis pneumonia, toxoplasmosis, malaria, and babesia.

Référence	Designation	Size	Information
SE-S3079-	Atovaquone	10	Atovaquone is a medication used to treat or prevent for
10mM/1mL		mM/1mL	pneumocystis pneumonia, toxoplasmosis, malaria, and babesia.
SE-S1835-25mg	Azithromycin	25 mg	Azithromycin is an antibiotic by inhibiting protein synthesis, used for the treatment of bacterial infections.
SE-S1835-50mg	Azithromycin	50 mg	Azithromycin is an antibiotic by inhibiting protein synthesis, used for the treatment of bacterial infections.
SE-S1835- 10mM/1mL	Azithromycin	10 mM/1mL	Azithromycin is an antibiotic by inhibiting protein synthesis, used for the treatment of bacterial infections.
SE-S1835-200mg	Azithromycin	200 mg	Azithromycin is an antibiotic by inhibiting protein synthesis, used for the treatment of bacterial infections.
AB-M5438-50mg	Azithromycin	50 mg	Azithromycin is an antibiotic by inhibiting protein synthesis, used for the treatment of bacterial infections.
AB-M5438-100mg	Azithromycin	100 mg	Azithromycin is an antibiotic by inhibiting protein synthesis, used for the treatment of bacterial infections.
SE-S5940-5mg	Bepotastine	5 mg	Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor that is indicated in allergic rhinitis, urticaria, and pruritus associated with skin disease.
SE-S5940-25mg	Bepotastine	25 mg	Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor that is indicated in allergic rhinitis, urticaria, and pruritus associated with skin disease.
SE-S5940-100mg	Bepotastine	100 mg	Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor that is indicated in allergic rhinitis, urticaria, and pruritus associated with skin disease.
SE-S3037-10mg	Bepotastine Besilate	10 mg	Bepotastine is a non-sedating, selective antagonist of histamine 1 (H1) receptor with pIC50 of 5.7.
SE-S3037-50mg	Bepotastine Besilate	50 mg	Bepotastine is a non-sedating, selective antagonist of histamine 1 (H1) receptor with pIC50 of 5.7.
SE-S3037- 10mM/1mL	Bepotastine Besilate	10 mM/1mL	Bepotastine is a non-sedating, selective antagonist of histamine 1 (H1) receptor with pIC50 of 5.7.
AB-M6166-5mg	Bevacizumab	5 mg	Humanized vascular endothelial growth factor (VEGF) antibody (bevacizumab; Avastin) is a highly effective monoclonal antibody against metastatic colorectal cancer and several other advanced late stage cancers.
SE-S5911-5mg	Bictegravir	5 mg	Bictegravir is a novel, potent, once-daily, unboosted inhibitor of HIV-1 integrase .
SE-S5911-25mg	Bictegravir	25 mg	Bictegravir is a novel, potent, once-daily, unboosted inhibitor of HIV-1 integrase .
AB-M9113-2mg	Bictegravir	2 mg	Bictegravir (GS-9883) is a novel, potent inhibitor of HIV-1 integrase with an IC50 of 7.5 nM.
AB-M9113-5mg	Bictegravir	5 mg	Bictegravir (GS-9883) is a novel, potent inhibitor of HIV-1 integrase with an IC50 of 7.5 nM.
AB-M9113-10mg	Bictegravir	10 mg	Bictegravir (GS-9883) is a novel, potent inhibitor of HIV-1 integrase with an IC50 of 7.5 nM.

Référence	Designation	Size	Information
SE-S3733-5mg	Boceprevir	5 mg	Boceprevir is an oral, direct acting hepatitis C virus (HCV) protease inhibitor with Ki value of 14 nM for NS3. It is used in combination with other antiviral agents in the treatment of chronic hepatitis C, genotype 1.
SE-S3733-25mg	Boceprevir	25 mg	Boceprevir is an oral, direct acting hepatitis C virus (HCV) protease inhibitor with Ki value of 14 nM for NS3. It is used in combination with other antiviral agents in the treatment of chronic hepatitis C, genotype 1.
SE-S3733-100mg	Boceprevir	100 mg	Boceprevir is an oral, direct acting hepatitis C virus (HCV) protease inhibitor with Ki value of 14 nM for NS3. It is used in combination with other antiviral agents in the treatment of chronic hepatitis C, genotype 1.
AB-M3624-5mg	Boceprevir	5 mg	Boceprevir (EBP-520, SCH503034) is an HCV protease inhibitor (Ki=14 nM) for the treatment of hepatitis C virus infection.
AB-M3624-10mg	Boceprevir	10 mg	Boceprevir (EBP-520, SCH503034) is an HCV protease inhibitor (Ki=14 nM) for the treatment of hepatitis C virus infection.
AB-M3624-25mg	Boceprevir	25 mg	Boceprevir (EBP-520, SCH503034) is an HCV protease inhibitor (Ki=14 nM) for the treatment of hepatitis C virus infection.
AB-M3624-50mg	Boceprevir	50 mg	Boceprevir (EBP-520, SCH503034) is an HCV protease inhibitor (Ki=14 nM) for the treatment of hepatitis C virus infection.
AB-M2487-50mg	Camostat Mesilate	50 mg	Camostat is a trypsin-like protease inhibitor, inhibits airway epithelial sodium channel (ENaC) function with IC50 of 50 nM, less potent to trpsin, prostasin and matriptase.
AB-M2487-100mg	Camostat Mesilate	100 mg	Camostat is a trypsin-like protease inhibitor, inhibits airway epithelial sodium channel (ENaC) function with IC50 of 50 nM, less potent to trpsin, prostasin and matriptase.
AB-M2152-10mg	Carfilzomib	10 mg	Carfilzomib (PR-171) is a novel and selective, irreversible proteasome inhibitor with IC50 of <5 nM.
AB-M2152-50mg	Carfilzomib	50 mg	Carfilzomib (PR-171) is a novel and selective, irreversible proteasome inhibitor with IC50 of <5 nM.
AB-M2152-100mg	Carfilzomib	100 mg	Carfilzomib (PR-171) is a novel and selective, irreversible proteasome inhibitor with IC50 of <5 nM.

Référence	Designation	Size	Information
SE-S2853-5mg	Carfilzomib (PR-171)	5 mg	Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β 5 subunit, but little or no effect on the PGPH and T-L activities.
SE-S2853-10mg	Carfilzomib (PR-171)	10 mg	Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β 5 subunit, but little or no effect on the PGPH and T-L activities.
SE-S2853-50mg	Carfilzomib (PR-171)	50 mg	Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β 5 subunit, but little or no effect on the PGPH and T-L activities.
SE-S2853-100mg	Carfilzomib (PR-171)	100 mg	Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β 5 subunit, but little or no effect on the PGPH and T-L activities.
SE-S2853- 10mM/1mL	Carfilzomib (PR-171)	10 mM/1mL	Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β 5 subunit, but little or no effect on the PGPH and T-L activities.
SE-S4157-50mg	Chloroquine diphosphate	50 mg	Chloroquine diphosphate is a 4-aminoquinoline antimalarial and anti-rheumatoid agent, also acting as an ATM activator.
AB-M2510-100mg	Chloroquine diphosphate	100 mg	Chloroquine diphosphate is a 4-aminoquinoline antimalarial and anti-rheumatoid agent.
AB-M2510-200mg	Chloroquine diphosphate	200 mg	Chloroquine diphosphate is a 4-aminoquinoline antimalarial and anti-rheumatoid agent.
SE-S1183-2mg	Danoprevir (ITMN- 191)	2 mg	Danoprevir(ITMN-191) is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM, inhibition effect for HCV genotypes 1A/1B/4/5/6 is ~10-fold higher than 2B/3A. Phase 2.
SE-S1183-5mg	Danoprevir (ITMN- 191)	5 mg	Danoprevir(ITMN-191) is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM, inhibition effect for HCV genotypes 1A/1B/4/5/6 is ~10-fold higher than 2B/3A. Phase 2.
SE-S1183- 10mM/1mL	Danoprevir (ITMN- 191)	10 mM/1mL	Danoprevir(ITMN-191) is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM, inhibition effect for HCV genotypes 1A/1B/4/5/6 is ~10-fold higher than 2B/3A. Phase 2

Référence	Designation	Size	Information
SE-S5250-25mg	Darunavir	25 mg	Darunavir is a nonpeptidic HIV protease inhibitor, used to treat HIV infection.
AB-M6094-5mg	Darunavir	5 mg	Darunavir is a nonpeptidic HIV protease inhibitor, used to treat HIV infection.
AB-M6094-10mg	Darunavir	10 mg	Darunavir is a nonpeptidic HIV protease inhibitor, used to treat HIV infection.
AB-M6094-50mg	Darunavir	50 mg	Darunavir is a nonpeptidic HIV protease inhibitor, used to treat HIV infection.
SE-S1620-5mg	Darunavir Ethanolate	5 mg	Darunavir Ethanolate (DRV) is a nonpeptidic HIV protease inhibitor, used to treat HIV infection.
SE-S1620-50mg	Darunavir Ethanolate	50 mg	Darunavir Ethanolate (DRV) is a nonpeptidic HIV protease inhibitor, used to treat HIV infection
AB-M3568-5mg	Darunavir Ethanolate	5 mg	Darunavir Ethanolate is an HIV protease inhibitor.
AB-M3568-10mg	Darunavir Ethanolate	10 mg	Darunavir Ethanolate is an HIV protease inhibitor.
AB-M3568-50mg	Darunavir Ethanolate	50 mg	Darunavir Ethanolate is an HIV protease inhibitor.
SE-S3035-10mg	Daunorubicin HCl	10 mg	Daunorubicin HCl inhibits both DNA and RNA synthesis and inhibits DNA synthesis with Ki of 0.02 µM in a cell-free assay. Daunorubicin is a topoisomerase II inhibitor that induces apoptosis .
SE-S3035-50mg	Daunorubicin HCl	50 mg	Daunorubicin HCl inhibits both DNA and RNA synthesis and inhibits DNA synthesis with Ki of 0.02 µM in a cell-free assay. Daunorubicin is a topoisomerase II inhibitor that induces apoptosis .
SE-S3035- 10mM/1mL	Daunorubicin HCl	10 mM/1mL	Daunorubicin HCl inhibits both DNA and RNA synthesis and inhibits DNA synthesis with Ki of 0.02 µM in a cell-free assay. Daunorubicin is a topoisomerase II inhibitor that induces apoptosis .
AB-M4824-2mg	Dolutegravir sodium	2 mg	Dolutegravir sodium is a potent, second generation HIV integrase inhibitor ($IC_{50} = 2.7 \text{ nM}$) that displays potent antiviral activity.
AB-M4824-5mg	Dolutegravir sodium	5 mg	Dolutegravir sodium is a potent, second generation HIV integrase inhibitor ($IC_{50} = 2.7 \text{ nM}$) that displays potent antiviral activity.
AB-M4824-10mg	Dolutegravir sodium	10 mg	Dolutegravir sodium is a potent, second generation HIV integrase inhibitor ($IC_{50} = 2.7 \text{ nM}$) that displays potent antiviral activity.
AB-M4824-50mg	Dolutegravir sodium	50 mg	Dolutegravir sodium is a potent, second generation HIV integrase inhibitor ($IC_{50} = 2.7 \text{ nM}$) that displays potent antiviral activity.
AB-M4824-100mg	Dolutegravir sodium	100 mg	Dolutegravir sodium is a potent, second generation HIV integrase inhibitor ($IC_{50} = 2.7 \text{ nM}$) that displays potent antiviral activity.
SE-S7975-5mg	Favipiravir (T-705)	5 mg	Favipiravir (T-705) is a potent and selective RNA-dependent RNA polymerase inhibitor, used to treat influenza virus infections.

Référence	Designation	Size	Information
SE-S7975-25mg	Favipiravir (T-705)	25 mg	Favipiravir (T-705) is a potent and selective RNA-dependent RNA polymerase inhibitor, used to treat influenza virus infections.
SE-S7975-100mg	Favipiravir (T-705)	100 mg	Favipiravir (T-705) is a potent and selective RNA-dependent RNA polymerase inhibitor, used to treat influenza virus infections.
SE-S9567-1mg	Indinavir Sulfate	1 mg	Indinavir sulfate is a specific and potent inhibitor of HIV-1 protease and is widely used in the treatment of AIDS.
AB-M2256-100mg	Ivermectin	100 mg	lvermectin is a positive allosteric modulator of the α7 neuronal nicotinic acetylcholine receptor and the purinergic P2X4 receptor.
AB-M2256-500mg	Ivermectin	500 mg	Ivermectin is a positive allosteric modulator of the $\alpha 7$ neuronal nicotinic acetylcholine receptor and the purinergic P2X4 receptor.
AB-M2256-1g	Ivermectin	1 g	Ivermectin is a positive allosteric modulator of the $\alpha 7$ neuronal nicotinic acetylcholine receptor and the purinergic P2X4 receptor.
SE-S7579-5mg	Ledipasvir (GS5885)	5 mg	Ledipasvir (GS5885) is a HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection.
SE-S7579-25mg	Ledipasvir (GS5885)	25 mg	Ledipasvir (GS5885) is a HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection.
SE-S1380-10mg	Lopinavir	10 mg	Lopinavir is a potent HIV protease inhibitor with Ki of 1.3 pM in a cell-free assay.
SE-S1380-100mg	Lopinavir	100 mg	Lopinavir is a potent HIV protease inhibitor with Ki of 1.3 pM in a cell-free assay
SE-S1380-200mg	Lopinavir	200 mg	Lopinavir is a potent HIV protease inhibitor with Ki of 1.3 pM in a cell-free assay
SE-S1380- 10mM/1mL	Lopinavir	10 mM/1mL	Lopinavir is a potent HIV protease inhibitor with Ki of 1.3 pM in a cell-free assay.
AB-M2158-50mg	Lopinavir	50 mg	Lopinavir (ABT-378) is a potent protease inhibitor.
AB-M2158-100mg	Lopinavir	100 mg	Lopinavir (ABT-378) is a potent protease inhibitor.
AB-M2158-250mg	Lopinavir	250 mg	Lopinavir (ABT-378) is a potent protease inhibitor.
AB-M3493-100mg	Mitoxantrone	100 mg	Mitoxantrone is a type II topoisomerase inhibitor with IC50 of 2.0 μ M, 0.42 mM for HepG2 and MCF-7/wt cells, respectively
SE-S2485-50mg	Mitoxantrone 2HCl	50 mg	Mitoxantrone is a type II topoisomerase inhibitor with IC50 of 2.0 μ M, 0.42 mM for HepG2 and MCF-7/wt cells, respectively.
SE-S2485-100mg	Mitoxantrone 2HCl	100 mg	Mitoxantrone is a type II topoisomerase inhibitor with IC50 of 2.0 μ M, 0.42 mM for HepG2 and MCF-7/wt cells, respectively.
SE-S2485- 10mM/1mL	Mitoxantrone 2HCl	10 mM/1mL	Mitoxantrone is a type II topoisomerase inhibitor with IC50 of 2.0 μ M, 0.42 mM for HepG2 and MCF-7/wt cells, respectively.

Référence	Designation	Size	Information
SE-S2079-10mg	Moexipril HCl	10 mg	Moexipril HCl is a potent orally active nonsulfhydryl angiotensin converting enzyme (ACE) inhibitor, used for the treatment of hypertension and congestive heart failure.
SE-S2079-50mg	Moexipril HCl	50 mg	Moexipril HCl is a potent orally active nonsulfhydryl angiotensin converting enzyme (ACE) inhibitor, used for the treatment of hypertension and congestive heart failure.
SE-S2079- 10mM/1mL	Moexipril HCl	10 mM/1mL	Moexipril HCl is a potent orally active nonsulfhydryl angiotensin converting enzyme (ACE) inhibitor, used for the treatment of hypertension and congestive heart failure.
AB-M5803-10mg	Nafamostat Mesylate	10 mg	Nafamostat mesilate is a synthetic serine protease inhibitor, used as an anticoagulant during hemodialysis.
AB-M5803-50mg	Nafamostat Mesylate	50 mg	Nafamostat mesilate is a synthetic serine protease inhibitor, used as an anticoagulant during hemodialysis.
SE-S4282-10mg	Nelfinavir Mesylate	10 mg	Nelfinavir Mesylate is a potent HIV protease inhibitor with Ki of 2 nM.
SE-S4282-50mg	Nelfinavir Mesylate	50 mg	Nelfinavir Mesylate is a potent HIV protease inhibitor with Ki of 2 nM
SE-S4282-200mg	Nelfinavir Mesylate	200 mg	Nelfinavir Mesylate is a potent HIV protease inhibitor with Ki of 2 nM.
AB-M3433-100mg	Nitazoxanide	100 mg	Nitazoxanide is a synthetic nitrothiazolyl-salicylamide derivative and an antiprotozoal agent. (IC50 for canine influenza virus ranges from 0.17 to 0.21 μ M)
AB-M3380-50mg	Pitavastatin Calcium	50 mg	Pitavastatin calcium is a novel member of the medication class of statins.
SE-S1759-50mg	Pitavastatin Calcium	50 mg	Pitavastatin calcium, a novel member of the medication class of statins , is a calcium salt formulation of pitavastatin which is a highly effective HMG-CoA reductase inhibitor.
SE-S1759-10mg	Pitavastatin Calcium	10 mg	Pitavastatin calcium, a novel member of the medication class of statins , is a calcium salt formulation of pitavastatin which is a highly effective HMG-CoA reductase inhibitor.
SE-S1759-200mg	Pitavastatin Calcium	200 mg	Pitavastatin calcium, a novel member of the medication class of statins , is a calcium salt formulation of pitavastatin which is a highly effective HMG-CoA reductase inhibitor.

Référence	Designation	Size	Information
SE-S1691-50mg	Praziquantel	50 mg	Praziquantel is an anthelmintic effective against flatworms.
SE-S1691- 10mM/1mL	Praziquantel	10 mM/1mL	Praziquantel is an anthelmintic effective against flatworms.
SE-S2071-25mg	Prulifloxacin (NM441, AF 3013)	25 mg	Prulifloxacin, the prodrug of ulifloxacin, is a broad- spectrum oral fluoroquinolone antibacterial agent.
AB-M3864-5mg	Remdesivir	5 mg	Remdesivir, also known as GS-5734, is a nucleoside analogue with in vitro activity against multiple RNA viruses, including Ebola and CoV. Remdesivir inhibits murine hepatitis virus (MHV) with an EC50 of 30 nM, and blocks SARS-CoV and MERS-CoV in HAE cells with EC50s of both 74 nM in HAE cells after treatment for 24 h. GS-5734 inhibits both epidemic and zoonotic coronaviruses. Remdesivir may be highly effective in the control of 2019-nCoV (COVID-19) infection in vitro.
AB-M3864-10mg	Remdesivir	10 mg	Remdesivir, also known as GS-5734, is a nucleoside analogue with in vitro activity against multiple RNA viruses, including Ebola and CoV. Remdesivir inhibits murine hepatitis virus (MHV) with an EC50 of 30 nM, and blocks SARS-CoV and MERS-CoV in HAE cells with EC50s of both 74 nM in HAE cells after treatment for 24 h. GS-5734 inhibits both epidemic and zoonotic coronaviruses. Remdesivir may be highly effective in the control of 2019-nCoV (COVID-19) infection in vitro.
AB-M3864-50mg	Remdesivir	50 mg	Remdesivir, also known as GS-5734, is a nucleoside analogue with in vitro activity against multiple RNA viruses, including Ebola and CoV. Remdesivir inhibits murine hepatitis virus (MHV) with an EC50 of 30 nM, and blocks SARS-CoV and MERS-CoV in HAE cells with EC50s of both 74 nM in HAE cells after treatment for 24 h. GS-5734 inhibits both epidemic and zoonotic coronaviruses. Remdesivir may be highly effective in the control of 2019-nCoV (COVID-19) infection in vitro.
SE-S8932-1mg	Remdesivir (GS-5734)	1 mg	Remdesivir,a monophosphoramidate prodrug of an adenosine analog, is an investigational broad-spectrum antiviral agent with in vitro activity against multiple RNA viruses, including Ebola and CoV.
SE-S8932-5mg	Remdesivir (GS-5734)	5 mg	Remdesivir,a monophosphoramidate prodrug of an adenosine analog, is an investigational broad-spectrum antiviral agent with in vitro activity against multiple RNA viruses, including Ebola and CoV.

Référence	Designation	Size	Information
AB-M3334-100mg	Ribavirin	200 mg	Ribavirin (Copegus) is an anti-viral agent indicated for severe RSV infection (individually), hepatitis C infection and other viral infections.
AB-M3334-200mg	Ribavirin	200 mg	Ribavirin (Copegus) is an anti-viral agent indicated for severe RSV infection (individually), hepatitis C infection and other viral infections.
AB-M3334-500mg	Ribavirin	500 mg	Ribavirin (Copegus) is an anti-viral agent indicated for severe RSV infection (individually), hepatitis C infection and other viral infections.
SE-S1185-10mg	Ritonavir	10 mg	Ritonavir is a Cytochrome P450 3A and Protease Inhibitor; Also inhibits Cytochrome P450 2D6, P-Glycoprotein and induces Cytochrome P450 2C19, Cytochrome P450 1A2, Cytochrome P450 2C9, Cytochrome P450 2B6 and UDP Glucuronosyltransferases.
SE-S1185-50mg	Ritonavir	50 mg	Ritonavir is a Cytochrome P450 3A and Protease Inhibitor; Also inhibits Cytochrome P450 2D6, P-Glycoprotein and induces Cytochrome P450 2C19, Cytochrome P450 1A2, Cytochrome P450 2C9, Cytochrome P450 2B6 and UDP Glucuronosyltransferases.
SE-S1185-100mg	Ritonavir	100 mg	Ritonavir is a Cytochrome P450 3A and Protease Inhibitor; Also inhibits Cytochrome P450 2D6, P-Glycoprotein and induces Cytochrome P450 2C19, Cytochrome P450 1A2, Cytochrome P450 2C9, Cytochrome P450 2B6 and UDP Glucuronosyltransferases.
SE-S1185- 10mM/1mL	Ritonavir	10 mM/1mL	Ritonavir is a Cytochrome P450 3A and Protease Inhibitor; Also inhibits Cytochrome P450 2D6, P-Glycoprotein and induces Cytochrome P450 2C19, Cytochrome P450 1A2, Cytochrome P450 2C9, Cytochrome P450 2B6 and UDP Glucuronosyltransferases.
AB-M2159-10mg	Ritonavir	10 mg	Ritonavir (ABT-538) is an HIV protease inhibitor used frequently as a booster of other protease inhbitors.
AB-M2159-50mg	Ritonavir	50 mg	Ritonavir (ABT-538) is an HIV protease inhibitor used frequently as a booster of other protease inhbitors.
AB-M2159-100mg	Ritonavir	100 mg	Ritonavir (ABT-538) is an HIV protease inhibitor used frequently as a booster of other protease inhbitors.
SE-S5072-10mg	Rosuvastatin	10 mg	Rosuvastatin is an inhibitor of HMG-CoA reductase , an enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis, with Ki value (inhibition constant) of approximately 0.1 nM.

Référence	Designation	Size	Information
SE-S5072-25mg	Rosuvastatin	25 mg	Rosuvastatin is an inhibitor of HMG-CoA reductase , an enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis, with Ki value (inhibition constant) of approximately 0.1 nM
SE-S5072-100mg	Rosuvastatin	100 mg	Rosuvastatin is an inhibitor of HMG-CoA reductase , an enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis, with Ki value (inhibition constant) of approximately 0.1 nM
SE-S2169-50mg	Rosuvastatin Calcium	50 mg	Rosuvastatin Calcium is a competitive inhibitor of HMG-CoA reductase with IC50 of 11 nM in a cell-free assay.
SE-S2169-100mg	Rosuvastatin Calcium	100 mg	Rosuvastatin Calcium is a competitive inhibitor of HMG-CoA reductase with IC50 of 11 nM in a cell-free assay.
SE-S2169- 10mM/1mL	Rosuvastatin Calcium	10 mM/1mL	Rosuvastatin Calcium is a competitive inhibitor of HMG-CoA reductase with IC50 of 11 nM in a cell-free assay.
AB-M2283-50mg	Rosuvastatin calcium	50 mg	Rosuvastatin (Crestor) is a member of statins and used to treat high cholesterol and related conditions.
AB-M2283-100mg	Rosuvastatin calcium	100 mg	Rosuvastatin (Crestor) is a member of statins and used to treat high cholesterol and related conditions.
AB-M6264-10mg	T-705	10 mg	Favipiravir (T-705) is a potent and selective RNA-dependent RNA polymerase inhibitor, used to treat influenza virus infections.
AB-M6264-25mg	T-705	25 mg	Favipiravir (T-705) is a potent and selective RNA-dependent RNA polymerase inhibitor, used to treat influenza virus infections.
AB-M6264-50mg	T-705	50 mg	Favipiravir (T-705) is a potent and selective RNA-dependent RNA polymerase inhibitor, used to treat influenza virus infections.
SE-S1538-5mg	Telaprevir (VX-950)	5 mg	Telaprevir (VX-950) is an HCV NS3-4A serine protease inhibitor with IC50 of 0.35 μ M.
SE-S1538-10mg	Telaprevir (VX-950)	10 mg	Telaprevir (VX-950) is an HCV NS3-4A serine protease inhibitor with IC50 of 0.35 μ M
SE-S1538-50mg	Telaprevir (VX-950)	50 mg	Telaprevir (VX-950) is an HCV NS3-4A serine protease inhibitor with IC50 of 0.35 μM
AB-M6223-5mg	Tocilizumab	5 mg	Tocilizumab is a humanized monoclonal antibody that binds to the interleukin-6 receptor, MW: 148 KD.
SE-S3724-25mg	Velpatasvir	25 mg	Velpatasvir is a second-generation NS5A inhibitor that inhibits hepatitis C viral replication through acting on the crucial "membranous web" that facilitates RNA replication.
SE-S3724-100mg	Velpatasvir	100 mg	Velpatasvir is a second-generation NS5A inhibitor that inhibits hepatitis C viral replication through acting on the crucial "membranous web" that facilitates RNA replication.

Inhibitors libraries



As a world-renowned supplier of small molecular compounds, TargetMol performed a Swiss-Model Homology Modelling process to generate reliable protein models or 3D protein structures of Spike- RBD, ACE2, Mpro (3CLpro), PLpro, nsp16, X domain, and RdRp (nsp12). These protein models provide sufficient information for virtual screening against key proteins of SARS-CoV-2.

Cat.No	Libraries	Amount
TA-L1710	Anti-COVID-19 Compound Library	2448
TA-L1800	Anti-Infection Compound Library	2977
TA-L1700	Anti-Viral Compound Library	800
TA-L9200	Drug Repurposing Compound Library	4240
TA-L1720	Nucleoside Compound Library	179

Proteins

Ref	Designation	Size	Expression system	Tag
E-PKSR030465	Recombinant 2019-nCoV 3C-like Proteinase Protein (His Tag)	10 μg	E.coli	N-6His
AL-RP01270LQ	Recombinant 2019-nCoV 3C-like Proteinase Protein with His tag and Avi tag	100 μg	E.coli	N-Avi- 6His
E-PKSR030473	Recombinant 2019-nCoV Guanine-N7_meth Protein (His Tag)	10 μg	E.coli	N-6His
E-PKSR030466	Recombinant 2019-nCoV Helicase Protein (His Tag)	10 μg	E.coli	C-6His
E-PKSR030467	Recombinant 2019-nCoV NSP1 Protein (His Tag)	10 μg	E.coli	C-6His
E-PKSR030471	Recombinant 2019-nCoV NSP10 Protein (His Tag)	10 μg	E.coli	N-6His
E-PKSR030468	Recombinant 2019-nCoV NSP2 Protein (His Tag)	10 μg	E.coli	C-6His
E-PKSR030469	Recombinant 2019-nCoV NSP7 Protein (His Tag)	10 μg	E.coli	C-6His
E-PKSR030470	Recombinant 2019-nCoV NSP8 Protein (His Tag)	10 μg	E.coli	C-6His
E-PKSR030472	Recombinant 2019-nCoV Papain-Like Protease Protein	10 μg	E.coli	
AL-RP01274LQ	Recombinant 2019-nCoV papain-like protease with His tag	100 μg	E.coli	N-6His
E-PKSR030489	Recombinant 2019-nCoV S-trimer Protein (His Tag)	1 mg	Human Cells	C-6His
E-PKSR030495	Recombinant Human APN Protein (His Tag)	10 μg	Human Cells	C-6His
E-PKSH032179	Recombinant Human Cathepsin B/CTSB Protein (His Tag)	10 μg	Human Cells	C-6His
E-PKSH032182	Recombinant Human Cathepsin L/CTSL Protein (His Tag)	10 μg	Human Cells	C-6His
E-PKSH032377	Recombinant Human CD147/Basigin Protein (His Tag)	10 μg	Human Cells	C-6His
E-PKSR030496	Recombinant Mouse APN Protein (His Tag)	10 μg	Human Cells	C-6His

Ref	Designation	Size	Expression system	Tag
E-PKSM040956	Recombinant Mouse Cathepsin B/CTSB Protein (His Tag)	10 μg	Human Cells	C-6His
E-PKSM041223	Recombinant Mouse CD147/Basigin Protein (His Tag)	10 μg	Human Cells	C-6His
EP-E80010-1	Recombinant SARS-CoV-2 3C-like Proteinase with His and Avi Tag	100 μg	E. coli	His and Avi Tag
EP-E80012-1	Recombinant SARS-CoV-2 Papain-like Protease with His-Tag	100 μg	E. coli	His-Tag
GTX01557-pro	SARS-CoV-2 (COVID-19) 3C-like Proteinase protein, His and Avi tag	100 μg	E. coli	His-Avi Tag
GTX135648-pro-S	SARS-CoV-2 (COVID-19) 3CLpro (nsp5) protein, His tag	100 μg	E. coli	His Tag
GTX135648-pro	SARS-CoV-2 (COVID-19) 3CLpro (nsp5) protein, His tag	100 μg	E. coli	His Tag

Substrates

Covidyte™ SARS-CoV-2 Substrate Series

Coronaviruses (CoVs) can infect humans and multiple species of animals, causing a wide spectrum of diseases. In late 2019, a novel coronavirus, termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was determined as a cause for several cases of respiratory disease (Covid-19). Even though most infected patients only suffer from mild symptoms such as fever and cough associated with a good prognosis, the disease can progress into fatal cases of pneumonia and acute respiratory failure, especially in older males with comorbidities. The virus rapidly spread worldwide. It has infected more than a million people, and Covid-19 has claimed more than seventy thousand fatalities (as of April 6, 2020). Currently, there are not any specific and effective options available for treating Covid-19. At present the clinical treatment of Covid-19 is mainly symptomatic combined with repurposing of already marketed antiviral drugs such as Remdesivir and antibiotics to treat secondary infections. There is an extremely urgent need for the development of specific antiviral therapeutics and vaccines against SARS-CoV-2. The coronavirus main protease, which plays a pivotal role in viral gene expression and replication through the proteolytic processing of replicase polyproteins, is an attractive target for anti-CoV drug design. The inhibition of viral proteases necessary for proteolytic processing of polyproteins has been a successful strategy in the treatment of human immunodeficiency virus (HIV) and hepatitis C respectively, proving the potential of protease inhibitors for the treatment of viral infections. Similarly, the main protease of SARS-CoV-2 is thought to be essential for viral replication and, therefore, is regarded as promising target for antiviral therapy of Covid-19.

Covidyte™ is a peptide substrate containing an amino acid sequence that can be cleaved by coronavirus proteases. The dark-FRET peptide contains a quencher and a donor on the N-and C-terminals respectively where the fluorescence is effectively quenched when the peptide is intact. When the peptide is hydrolyzed by coronavirus proteases, the fragment generates significantly enhanced fluorescence since its fluorescence is no longer quenched. The activity of coronavirus proteases can be effectively monitored by the fluorescence intensity. Covidyte™ is a convenient tool for screening inhibitors of coronavirus proteases.

Catalog Number	Name	Size	Molecular weignt	Emission (nm)	Excitation (nm)	Extinction coefficient (cm ⁻¹ M ⁻¹)	Amino acid sequence
13535-AAT	Covipyte™ EN450	100 T	2584.98	336	455	5900	KTSAVLQSGFRKME
13536-AAT	Covipyte™ EN450	1 000 T	2584.98	336	455	5900	KTSAVLQSGFRKME
13540-AAT	Covidyte™ TF670	100 T	3620.33	649	664	25000	KTSAVLQSGFRKME
13541-AAT	Covidyte™ TF670	1 000 T	3620.33	649	664	25000	KTSAVLQSGFRKME
13537-AAT	Covidyte™ ED450	100 T	2034.36	336	455	5900	KTSAVLQSGFRKME
13538-AAT	Covidyte™ ED450	1 000 T	2034.36	336	455	5900	KTSAVLQSGFRKME
13542-AAT	Covidyte™ IF670	100 T	3067.69	656	670	25000 ¹	VNSTLQSGLRKM
13543-AAT	Covidyte™ IF670	1 000 T	3067.69	656	670	25000 ¹	VNSTLQSGLRKM

¹: Covidyte[™] IF670 extinction coefficient was measured with aqueous buffer (pH 7.2), its quantum yield is 0.25

Covipyte™ EN450

Coronaviruses (CoVs) can infect humans and multiple species of animals, causing a wide spectrum of diseases. In late 2019, a novel coronavirus, termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was determined as a cause for several cases of respiratory disease (Covid-19). Even though most infected patients only suffer from mild symptoms such as fever and cough associated with a good prognosis, the disease can progress into fatal cases of pneumonia and acute respiratory failure, especially in older males with comorbidities. Covid-19 rapidly spread worldwide. It has infected more than 4.3 million people and claimed more than three hundred thousand fatalities (as of May 14, 2020). Coronavirus is a single-stranded RNA positive-strand envelope type B coronavirus. Like the other two coronaviruses that cause SARS (Severe Acute Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome), SARS-CoV-2 encodes nonstructural, structural, and accessory proteins. Non-structural proteins include 3-chymotrypsin-like protease (3CLpro), papain-like protease, helicase, and RNA-dependent RNA polymerase (RNA -dependent RNA polymerase (RdRp). Structural proteins include spike glycoproteins. Papain in coronavirus operates on more than 11 cleavage sites on the large polyprotein 1ab. Processing of polyproteins translated from viral RNA is essential, therefore, the main proteases are identified as an attractive drug targets for preventing virus imitation. Papain-like protease (PLpro) of coronaviruses carries out proteolytic maturation of non-structural proteins that play a role in replication of the virus and performs deubiquitination of host cell factors to scuttle antiviral responses.

Covipyte™ EN450 is a peptide substrate containing 9 amino acid sequence (RELNGGAPI) that can be cleaved by coronavirus PLpro. The dark-FRET peptide contains Edans (donor) and Dabcyl (quencher) on the N-and C-terminals respectively where the fluorescence of Edans is effectively quenched by Dabcyl when the peptide is intact. When the peptide is hydrolyzed by coronavirus proteases, the Edans fragment generates significantly enhanced fluorescence since its fluorescence is no longer quenched by Dabcyl. The activity of coronavirus proteases can be effectively monitored by the fluorescence intensity of Edans. Covipyte™ EN450 is a convenient tool for screening and studying kinetics of PLpro inhibitors.

Catalog Number	Name	Size	Emission (nm)	Excitation (nm)	Extinction coefficient (cm ⁻¹ M ⁻¹)
13545-AAT	Covipyte™ EN450	100 Tests	336	455	5 900
13546-AAT	Covipyte™ EN450	1 000 Tests	336	455	5 900